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Human leukocyte antigen (HLA) polymorphism and the genetic diversity of human 
immunodeficiency virus (HIV) are the major obstacles for designing an effective HIV 
Cytotoxic T Lymphocytes (CTLs) based vaccine. Interestingly, recent studies have 
demonstrated that multiple class I alleles can recognize common epitopes “supertopes” due to 
the homology of amino acids within the major binding pockets of the peptide binding cleft. 
The implications of this for vaccine design is that a vaccine containing a small number of highly 
promiscuous supertopes can confer protection against a wide range of HIV variants. This 
notion makes supertopes immunogen design an attractive option. However, it is not clear 
whether supertopes presented in the context of different class I HLA alleles would induce 
functional equivalent CTL responses.   
In this study, we investigated the inhibitory activity of CTLs targeting identical epitopes 
presented by class I HLA alleles from the same superfamily. The viral inhibitory activity was 
measured using a newly developed CEM-GFP reporter T-cell line (GXR-cell) as target cell. 
We first compared the inhibitory activity of CTLs from 8 subjects targeting TPQDLNTML 
(Gag p24 residue 180-188-TL9) epitope presented by HLA-B*81:01 or B*42:01 alleles. We 
then assessed the inhibitory activity of the 8 subjects’ CTLs when presented with in-vivo 
occurring mutant (Q182S)-TL9 epitope by HLA-B*81:01 or B*42:01 alleles. Furthermore, we 
compared the inhibitory activity of CTLs from 4 subjects targeting ISPRTLNAW (Gag p24 
residue 147-155-IW9) epitope presented by HLA-B*57:03 or B*58:01 alleles.  
Comparative analysis of the inhibitory activity of the 8 subjects’ CTLs showed no 
statistical significant difference when TL9 epitope was presented by HLA-B*81:01 or B*42:01 
alleles (1:1; p-value = 0.8785, paired t test), even at low target to effector ratio (1:8; p-value = 
0.4418). No statistical significant difference was observed in the inhibitory activity of the 8 
subjects’ CTLs when mutant (Q182S)-TL9 epitope was presented by HLA-B*81:01 or 
B*42:01 alleles (1:1; p-value = 0.8042), same result was observed at low target to effector ratio 
(1:8; p-value = 0.9396).  
Comparative analysis of the inhibitory activity of the 4 subjects’ CTLs targeting 
identical IW9 epitopes presented by HLA-B*57:03 or B*58:01 alleles showed a trend towards 
significance at target to effector ratio 1:1 (1:1; p-value = 0.0924), but at low target to effector 
ratio, no significance difference was observed (1:8; p-value = 0.1496). 
In conclusion, we have demonstrated that there is no observable significant difference 




presented in the context of HLA-B*81:01 or B*42:01 alleles. Thus, TL9 epitope could be 
immunogenic for individuals expressing HLA-B*81:01 or B*42:01 alleles. We have also 
shown that the inhibitory activity of CTLs targeting identical IW9 epitopes presented by HLA-
B*57:03 or B*58:01 alleles is comparable. Indicating that IW9 epitope could be included in 
immunogen design for individuals expressing HLA-B*57:03 or B*58:01 alleles. These 
findings are relevant for HIV vaccine approach that seeks to identify immunogenic supertopes 























AIDS  Acquired immune deficiency syndrome 
APC  Antigen Presenting Cell 
CA  Capsid 
CCR5  Chemokine Receptor 5 
CD4+ T cells Human T cells expressing CD4+ antigen 
CD8+ T cells Human T cells expressing CD8+ antigen 
cDNA  Complementary deoxyribonucleic acid 
CDR  Complementary determining region 
CTL  Cytotoxic T lymphocyte 
CXCR4 CXC chemokine receptor 4 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic acid 
ELISA  Enzyme linked immunosorbent assay 
ELISPOT Enzyme linked immunosorbent spot assay 
Env  Envelope 
FACS  Fluorescent activated cell sorting 
FCS  Fetal Calf Serum 
Gag  Group-specific antigen 
GALT  Gut associated tissue 
GIT  Gastrointestinal tract 
GXR  CEM-GFP GXR25 
HAART Highly active antiretroviral treatment 
HIV  Human immunodeficiency virus 
HLA  Human leukocyte antigen 
ICS  Intracellular cytokine staining 
INFƳ  Interferon gamma 
MA  Matrix 
MHC  Major histocompatibility complex 
mRNA  Messenger ribonucleic acid 
Nef  Negative regulatory factor 
NC  Nucleocapsid (p7) 




PBS  Phosphate buffered saline 
PBMC  Peripheral blood mononuclear cells 
Pol  Polymerase 
Rev  Regulator of virion expression protein 
RNA  Ribonucleic acid 
SIV  Simian immunodeficiency virus 
SSO  Sequence specific oligonucleotide 
Tat  Transactivator of transcription 
TCR  T cell receptor 
Vif  Viral infectivity factor 
Vpr  Viral protein R 
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The isolation of human immunodeficiency virus (HIV) in 1983 has led to more than three 
decades of intense research on its structure and pathogenesis. Most of the work has been 
motivated by the need to develop new approaches to test, treat and prevent HIV infections 
(Barre-Sinoussi et al., 2013). Highly active antiretroviral treatment (HAART) has proven to be 
effective in controlling disease progression and transmission by reducing the viral load (Tanser 
et al., 2013, Bor et al., 2013). However, HAART is faced with several limitations such as; the 
development and transmission of drug resistant viruses, occurrence of drug toxicity, cost 
implication of obtaining the drugs and non-adherence of patients to therapy (Pontali, 2005, 
Tozzi, 2010, Falutz, 2011).  
The development of a safe and effective HIV vaccine remains the best hope to control 
HIV epidemic (Verma et al., 2015). Like other vaccines, a preventive HIV vaccine could help 
save millions of lives. Induction of broadly neutralizing antibodies and HIV-specific Cytotoxic 
T lymphocytes (CTLs) are the two immune effectors that HIV vaccine research has focused 
on. Although broadly neutralising antibodies are the best correlate of protection for many viral 
vaccines (Plotkin, 2010, Amanna and Slifka, 2011), eliciting neutralizing antibodies against 
HIV has been difficult due to rapid mutation rates of HIV (Amanna and Slifka, 2011). Hence, 
inducing functional CTLs response provides a very viable option.  
Data have shown the importance of the CTLs response in controlling HIV infection (Jin 
et al., 1999, Schmitz et al., 1999). CTLs can recognize and kill HIV-infected cells by specific 
recognition of viral epitopes presented by class I HLA molecules (Yang et al., 1997). However, 
huge genetic diversity of the class I HLA molecules and the considerable genetic variation of 
HIV are the major obstacles for designing effective HIV CTL-based vaccine.  
In order to develop HIV CTL-based vaccine, it would be important to define effective 
CTLs responses directed against HIV epitopes presented on the surface of infected cells (Yang 
et al., 1997, Sacha et al., 2007, Bennett et al., 2008). The benchmark towards this goal is to 







1.2 Global Overview of HIV/AIDS Epidemic 
 
Human immunodeficiency virus (HIV) is the aetiological agent of acquired immune deficiency 
syndrome (AIDS) and is one of the most devastating pathogens worldwide. Following its 
isolation in 1983, HIV has evolved to become a threat to global health (De Cock et al., 2012). 
Since the discovery of HIV, approximately 25 million AIDS related deaths have been recorded. 
In 2013, an estimate of 35 million people were living with HIV globally. In the same year, 
approximately 2.3 million new infections occurred, a number that is still high despite it being 
33% decline from the 3.4 million infections that occurred in 2001 (UNAIDS, 2013).  
More than two-thirds of HIV infections, roughly 24.7 million persons, were in Sub-
Saharan Africa which also accounted for close to 80% of women and 90% of children living 
with HIV (De Cock et al., 2012). South and south-east Asia accounted for approximately 4 
million HIV infected persons, and the Americas, including the Caribbean, accounted for 3 
million, (Figure 1). Despite the decline in the new infections, South Africa, in the Sub-Saharan 
Africa region, still bears the highest burden of HIV epidemic globally  (UNAIDS, 2013). 
 
Figure 1: Global View of the Estimated Number of People Living with HIV in 2013. The 
HIV pandemic affects all regions of the world, but Sub-Saharan Africa is the most affected 
region with approximately 24.7 million HIV infected individuals (UNAIDS, 2013). 
 
1.2.1 HIV/AIDS Epidemic in South Africa 
 
South Africa is the most affected country in the Sub-Saharan region by HIV pandemic (Shisana 




17.9 % in 15 to 49 year old people, and an estimated 6.1 million people were living with 
HIV/AIDS (UNAIDS, 2013). Provincial data on HIV prevalence is shown in Figure 2. The 
results show substantial variation of HIV prevalence by province. KwaZulu-Natal continue to 
lead South Africa in HIV prevalence (16.9%), followed by Mpumalanga (14.1%), Free State 
(14.0%) and North West (13.3%). The Western Cape had the lowest HIV prevalence (5%) 
followed by the Northern Cape (7.4%) and Limpopo (9.2%). In most provinces, HIV 
prevalence in women; aged 15 years and above, remains significantly higher than in men 
(Shisana and Onoya, 2014).    
 
 
Figure 2: Overall HIV Prevalence by Province in South Africa. KwaZulu-Natal is the most 
affected province while the Western Cape is the least affected province. Key: KZN-KwaZulu-
Natal, MP-Mpumalanga, FS-Free State, NW-North West, GP-Gauteng, EC-Eastern Cape, 
LP-Limpopo, NC-Northern Cape, WC-Western Cape (Shisana and Onoya, 2014). 
 
1.3 Molecular Biology of HIV 
1.3.1 Structure of HIV Virion 
 
HIV is a retrovirus belonging to the Retroviridae family and Lentivirus genus with a genome 
of approximately 10 kilobase (kb) in size (Ratner et al., 1985). Like other viruses, HIV can 
only survive and replicate upon infection of a host cell expressing its corresponding receptor  
(Smith and Daniel, 2006). Outside the host cell, HIV exists as a spherical particle called ‘virion’ 




HIV possess a lipid bilayer membrane that surrounds the viral Envelope glycoprotein and some 
cellular proteins (Sierra et al., 2005). The Envelope glycoprotein is heterodimer of the gp120 
which is attached to the gp41 (transmembrane glycoprotein).  
                      
 
Figure 3: Schematic Representation of HIV Virion. Inside the virion is the conical capsid. 
The capsid contains the enzymes reverse transcriptase, integrase and protease, and the viral 
genome. Two copies of single-(+) stranded RNA molecules, which are complexed by the 
nucleocapsid protein p7. The capsid is surrounded by lipid membrane. The viral glycoprotein 
gp41 and host cell surface proteins are integrated into the viral membrane, (Freed, 1998). 
 
HIV encodes 9 proteins; 3 major structural proteins (Gag, Pol and Env) are required for 
the formation of new virus particles, accessory proteins (Vif, Vpr, Vpu, and Nef), and 
regulatory proteins (Tat and Rev) are essential for regulatory function and virion assembly 
(Frankel and Young, 1998). 
The Gag gene encodes a polyprotein that is cleaved by viral protease to mature Gag 
proteins (p17, p24, p7 and p6). The matrix (p17), which is surrounded by the capsid (p24), 
ensures the integrity of the virion particle. The matrix is important for the incorporation of viral 




1998). The capsid forms the cone shaped shell of the mature virion that encloses the viral 
genomic RNA (Gelderblom et al., 1987), and plays a crucial role in virus assembly and 
maturation (Freed, 1998). The nucleocapsid, found in the core tightly associated with the viral 
RNA, is required for the encapsidation of the viral RNA, membrane binding, preintegration 
and transcription (Accola et al., 1998, Freed, 2001). The single stranded RNA and the enzymes; 
reverse transcriptase (RT), protease (PR), ribonuclease and integrase (IN), which are important 
for the virion development are tightly bound to the protein p7. The protein p6, located at the 
C-terminal of Gag is essential for the release of assembled virion from the cell surface (Paxton 
et al., 1993, Kondo and Gottlinger, 1996). 
The pol gene encodes a polyprotein, which is then cleaved by viral protease to produce 
viral enzymes reverse transcriptase, protease and integrase, (Figure 4). Reverse transcriptase 
catalyses the conversion of single stranded RNA into double stranded DNA, while integrase 
catalyses the insertion of linear double stranded viral DNA into the host cell chromosome (Hill 
et al., 2005). Protease cleaves the Gag and the Gag-Pol polyproteins and allows conformational 
changes within the particle to produce mature infectious viruses (Frankel and Young, 1998).  
Synthesis of the Env gp160 takes place in the endoplasmic reticulum and then 
transported through the secretory pathway to the plasma membrane (Murakami, 2008). The 
Env protein is heavily glycosylated and cleaved by cellular protease into surface subunit 
proteins; gp120 and transmembrane gp41 (Chan and Kim, 1998, Freed, 2001). The other 6 
genes encode the proteins that antagonise host defence and enhance pathogenicity (Freed, 
2001). These genes are known as vif (viral infectivity), vpu (viral protein U), vpr (viral protein 
R), nef (negative regulator protein), tat (transactivator protein) and rev (regulator of expression 





Figure 4: Schematic Representation of HIV Genome. The diagram indicates the regions 
coding for HIV proteins (Freed, 2001). 
   
1.3.2 HIV Replication 
 
The life cycle of HIV can be divided into early and late phase. The early phase involves: 
binding and entry, uncoating, reverse transcription and provirus integration. The late phase 
includes: virus protein synthesis, budding and maturation (Fanales-Belasio et al., 2010).  
In the early phase, HIV particles bind specifically to CD4 expressing cells through the 
interaction between surface subunit Env protein (gp120) and the co-receptors; such as CCR5 
and CXCR4 (Sierra et al., 2005, Bartolo et al., 2009). This interaction triggers a conformational 
change in gp120 which uncovers the transmembrane Env protein (gp41) binding site. After 
binding to the co-receptor, the virus and cellular membrane fuse thereby allowing for uncoating 
and release of the viral core into the host cell (Freed, 2001, Gomez and Hope, 2005). The single 
stranded viral RNA is then reverse transcribed by the enzyme reverse transcriptase to double 
stranded DNA which is then transported to the nucleus of the host cell (Pomerantz and Horn, 
2003). Following transportation to the nucleus, the viral DNA is then integrated with the host 
cell genome by the enzyme integrase.   
 the late phase, viral mRNA transcripts are synthesized and transported out of the 
nucleus for translation into proteins such as; gag-pol, env and nef (Sierra et al., 2005). These 




are cleaved by the enzyme protease to produce independent enzymes as well as structural 
proteins of a mature viral particle (de Oliveira et al., 2003). (Figure 5). 
 
 
Figure 5: Schematic Overview of HIV Replication Cycle. The replication cycle can be 
divided into early and late phase; the early phase is described with points 1-6, while the late 
phase is described with points 7-13, (Engelman and Cherepanov, 2012). 
 
1.4 HIV Pathogenesis 
 
Exposure to HIV is primarily through the mucosal route; either gastrointestinal or reproductive 
tracts, which is thought to result in initial local replication of the virus within target cells of the 
mucosal tissue (Douek et al., 2003), followed by systematic spread with considerable 
dissemination in the gut-associated lymphoid tissue (GALT) (Yuki et al., 2007). The 
establishment of HIV infection is dependent on the target cells expression of CD4 and a 
chemokine receptor (CCR5 or CXCR4), (Doms, 2001). The course of HIV infection can be 
categorized into 3 phases as illustrated in (Figure 6); (1) the acute phase, (2) the asymptomatic 






Figure 6: HIV Pathogenesis. Representation of a typical course of HIV infection showing 
CD8+ T and CD4+ T-cells dynamics and viral load changes over-time of infection (Munier 
and Kelleher, 2007). 
 
1.4.1 The Acute Phase 
 
Following transmission of HIV, approximately 10 days is required for viral RNA to be 
detectable in the plasma (McMichael et al., 2010). During this acute phase, diagnosis of acute 
HIV infection is often missed because the symptoms are common to many other infections 
(Altfeld and Walker, 2001). HIV replicates rapidly during the acute phase of infection with 
viral titres reaching a peak, usually more than a million RNA copies per ml of blood. CD4+ T-
cells numbers are significantly lowered at the time of peak viremia (McMichael et al., 2010). 
Subsequently, the emergence of CD8+ T-cell responses coincides with a decrease in viremia 
(Mogensen et al., 2010), suggesting that the suppression of viral replication is largely mediated 
by CD8+ T-cell (McMichael et al., 2010).  
A few studies have measured HIV-specific CD8+ T-cell responses during early HIV 
infection (Borrow et al., 1994, Koup et al., 1994, Pantaleo et al., 1994, Wilson et al., 2000, 
Ndhlovu et al., 2015). The CD8+ T-cell responses peaks at about 1-2 weeks later as the viremia 




sequence start to change dramatically (McMichael et al., 2010). As viremia decline to the viral 
set point, rapid selection of mutations occurs at discrete sites in the virus genome (Bernardin 
et al., 2005, Salazar-Gonzalez et al., 2009). Further studies on the early events during the acute 
phase of HIV infection may be critical in determining the course of diseases progression. 
 
1.4.2 Asymptomatic Phase 
 
The asymptomatic phase of HIV infection is where the viral load reaches a viral set-point 
(McMichael et al., 2010). During this phase, there is a gradual decline in the circulating CD4+ 
T-cells and loss of immune function. The decline in the CD4+ T-cells is not only caused by 
direct infection but also as a result of chronic immune activation and inflammation (Appay and 
Sauce, 2008). Furthermore, the immune system becomes progressively exhausted and there is 
a decline in its ability to regenerate the depleted CD4+ T-cells (Ndhlovu et al., 2015). The 
steady replication of HIV results in progressive exhaustion of CD8+ T-cells, thus impairing the 
ability of the immune system to control the virus (Appay and Sauce, 2008, McMichael et al., 
2010).  
 
1.4.3 The AIDS Phase 
 
In the absence of antiretroviral treatment, HIV establishes a chronic, progressive infection of 
human immune system that invariably, over the course of the years, leads to its destruction and 
severe immunodeficiency (Douek et al., 2003). The AIDS phase is defined by the rapid decline 
in the CD4 cell count with an increase in viral load. At this phase, the host becomes highly 
susceptible to opportunistic infections (e.g. tuberculosis, pneumococcal infections, oral 
candidiasis) and certain cancer (e.g. Kaposi’s sarcoma) (Paranjape, 2005). The average time 
from infection to AIDS is 8-10 years, but this may vary considerably due to host and viral 
factors (Derdeyn and Silvestri, 2005, Chatterjee, 2010). At this phase of advanced disease, the 
immune system is overwhelmed and death ensues as a result of the opportunistic infections. 
The loss of HIV-specific immunity might play a role in the steady acceleration of viral 







1.5 CYTOTOXIC T LYMPHOCYTES (CTLs) 
 
Cytotoxic T lymphocytes (CTLs), also referred to as CD8+ T-cells, are the host’s major 
defence mechanism against invading intracellular pathogens (Lehmann-Grube et al., 1985). 
CTLs are thought to control HIV replication and help to maintain clinical stability in infected 
individuals (Borrow et al., 1994, Koup et al., 1994). The intimate involvement of CTLs in the 
control of HIV will be discussed in the following sub-sections. 
 
1.5.1 History of HIV-Specific CTL 
 
HIV-specific CTL was first isolated in 1987 by Walker et al., (1987) and Plata et al., (1987). 
The high frequencies of HIV-specific CTLs in HIV infected individuals was detected by 
measuring the ability of freshly isolated Peripheral blood mononuclear cells (PBMCs) to lyse 
autologous B cells infected with recombinant vaccinia-HIV vector (Walker et al., 1987) or by 
peptide pulse targets (Nixon et al., 1988). Subsequent studies using other approaches such as 
detection of interferon γ ELISPOT (Dalod et al., 1999), intracellular cytokines (Maecker et al., 
2001) and peptide major histocompatibility complex (MHC) tetramer assay (Altman et al., 
1996), confirmed and quantified CTLs robustness in HIV infected individuals. Rapid 
expansion and the ability of single CTL to destroy more than one target cell, while sparing 
“innocent” bystanders, make CTLs very efficient Ag-specific effector cells (Broere et al., 
2011). 
 
1.5.2 CTLs Differentiation 
 
The development of CTLs is a multistep process with several built-in check points to ensure 
appropriate differentiation. Progenitor T-cells migrate to the thymus from the bone marrow; 
where they are produced. At this phase, the cells only express CD44 (adhesion molecule) and 
CD25 (α chain of the IL-2 receptor). Subsequently, they differentiate to express CD3 and CD8 
molecules in the thymus. The differentiated cells become committed to TCR lineage 
rearrangement. Cells bearing the T cell receptors that have high affinity for binding self-
peptides presented on Major histocompatibility complex (MHC I) are deleted, while those that 
do not recognise self-peptides are positively selected and exit the thymus to the periphery as 





1.5.3 Activation of Naïve CTL   
 
Activation of naïve CTL requires specific recognition of cognate peptide presented by antigen 
presenting cell (APC), and a costimulatory signal, (Figure 7), (Abbas et al., 1996). In the case 
of HIV, naïve CTL usually encounter HIV antigenic peptide in a secondary lymphoid organ. 
Upon priming with HIV antigen, naïve CTL undergo activation, proliferation, clonal expansion 
and differentiation into effector T cells, most of which are short lived (Abbas et al., 1996).   
The effect of HIV-specific CTL is seen in the vigorous destruction of infected cells 
presenting the cognate peptides. Most of these HIV-specific CTLs die by apoptosis after 
eliciting their effector function. A few of the effector T cells mature into memory T cells, which 
can respond faster and more effectively upon re-encountering their cognate antigen (Roderick 
Nairn., 2007).     
 
Figure 7: Activation of Naïve CTL. The APC (brown) presents antigenic peptide to the naïve 
CTL (yellow). Recognition of antigenic peptide coupled with the costimulatory signal activates 
the naïve CTL and differentiate it to effector T-cell. 
 
1.5.4 Mechanism of Action of HIV-specific CTL 
 
An HIV-specific CTL recognizes its cognate peptide fragment of 8 to 12 amino acids in length 
presented by the infected cell. This peptide fragment is generated intracellularly through 
protein degradation. The fragmented peptide is loaded into the class I human leukocyte antigen 
(HLA) molecule and transported to the cell surface for presentation to HIV-specific CTL  




molecule and viral peptide (Figure 8), and this recognition triggers the CTL to lyse the infected 
cell by releasing effector molecules such as perforins and granzymes. These effector molecules 
are capable of direct killing of the infected cells or inducing apoptosis in them (Gandhi and 
Walker, 2002). Thus, CTL responses in an individual may depend on the TCR repertoire that 
recognise the restricted peptide, expressed class I HLA allele and the peptide presented. 
 
Figure 8: Schematic Representation of HIV-Specific CTL Mechanism of action. The 
infected cell process the viral peptide and present to CTL via class I HLA molecule. CTL 
recognizes the presented peptide and releases effector molecules on the infected cell, thereby 
resulting in the killing of the infected cell (Yewdell et al., 2003, Jixin Zhong, 2011). 
 
1.5.5 CTL Receptors 
 
The CTL receptors (TCRs) are surface heterodimers consisting of disulphide-linked α- and β-
chains. Each TCR chain is composed of variable and constant Ig-like domains, followed by a 
transmembrane domain and a short cytoplasmic tail (Davis and van der Merwe, 1996). CTL 
recognizes peptides presented by the infected cell through the α/β binding site of the TCR 
(Turner et al., 2006). The binding of the peptide fragment takes place through the three loop 
region on each of α and β chains and the complementarity determining regions (CDRs). The 
CDR is composed of three domains; CDR1, CDR2 and CDR3. The CDR3 is mainly involved 




class I HLA molecule (Figure 9). In most TCRs, CDR1 has limited interaction with the peptide 
fragment and the class I HLA molecule (Rudolph et al., 2006). Studies have suggested that 
engineered TCRs might provide a means of generating HIV-specific polyfunctional T-cell 
responses and can engage epitope variants presented by the infected cells (Price et al., 2004, 
Varela-Rohena et al., 2008, Chen et al., 2012). Hence, engagement of TCRs could be 
modulating virus inhibitory capacity and recognition of naturally occurring HIV peptides.  
          
Figure 9: Position of the TCR CDRs Over the Class I HLA Allele/Peptide Surface. CDR1, 
CDR2 and CDR3 are colored in magenta, green and red respectively (Zoete et al., 2013). CDR3 
is mainly involved in the interraction with the peptide preseneted by the class I HLA molecule.  
                                     
1.5.6 The Role of HIV-specific CTL in HIV Infection 
 
There is a substantial evidence on the significant role that HIV-specific CTLs play in 
combating viral replication during the acute infection phase (Pantaleo et al., 1994). The 
massive expansion of HIV-specific CTLs few days after exposure to HIV coincide with the 
decline in plasma viremia (Koup et al., 1994, Ndhlovu et al., 2015). HIV-specific CTLs are 
thought to be responsible for the initial control of viral replication with viral control from both 
blood and lymph nodes (Borrow et al., 1997, Ndhlovu et al., 2015). In addition, in-vivo studies 
on the control of viremia in macaques during primary simian immunodeficiency virus (SIV) 




(Schmitz et al., 1999, Jin et al., 1999, Schmitz et al., 2005). In-vitro assay has also shown that 
the CTLs taken from HIV infected individuals are able to inhibit viral replication in autologous 
CD4+ T-cells (Yang et al., 1996). However, the factor influencing the effectiveness of the HIV-
specific CTL responses in controlling viral replication and in subsequently establishing 
different viral set points in individuals remains elusive. 
 
The relationship between the earliest CTL responses, viral set point and disease 
progression remains controversial (Walker and McMichael, 2012). Studies have suggested that 
the initial CTL responses are low in magnitude and narrowly directed towards viral proteins 
(Dalod et al., 1999, Altfeld et al., 2001, Cao et al., 2003a, Radebe et al., 2011). The responses 
may be localized at the inductive sites within the lymphoid tissue (Altfeld et al., 2002), and are 
regarded as the most effective in controlling viral replication as they have the greatest antiviral 
activity (Cao et al., 2003a). Although most of these detectable responses persist even in the 
chronic phase of infection (Koibuchi et al., 2005), most of them are less effective in further 
reducing the viral load. Thus, there is a need to understand the causes of ineffectiveness of the 
persistent responses at the chronic phase.  
 
1.5.7 HIV-Specific CTL Responses during the Chronic Phase of Infection 
 
Despite the presence of HIV-specific CTLs in chronic phase, majority of HIV infected patients 
still lose viral control (Addo et al., 2003, Draenert et al., 2004b, Frahm et al., 2004). Reported 
data from various studies on the immune correlate of HIV-specific CTL with viral load at 
chronic phase of infection have not been consistent (Ogg et al., 1998, Betts et al., 1999, Shankar 
et al., 2000, Betts et al., 2001, Migueles and Connors, 2001). On the other hand, specificity of 
responses during the chronic phase of infection repeatedly suggests that Gag targeting is 
associated with lower viral load (Edwards et al., 2002, Zuniga et al., 2006, Kiepiela et al., 2007, 
Geldmacher et al., 2007, Ndhlovu et al., 2015), while Env-specific response is associated with 
higher viral load (Ngumbela et al., 2008). These findings suggest that responses targeting Gag 
epitopes could be effective in reducing the rate of HIV disease progression. 
   
1.5.8 Gag-Specific CTL Responses are Superior 
 
While the overall breadth and magnitude of the CTL responses does not correlate with the rate 




preferential Gag-specific CTL responses and favourable clinical outcomes among other HIV 
proteins. Zuniga and colleagues (2006) showed that the contribution of Gag p24-CTL 
responses is positively associated with low viral load and high CD4+ T-cell counts. This was 
further confirmed with a large population study infected with clade C virus (Kiepiela et al., 
2007), showing a correlation between the number of CTLs responses to the conserved Gag-
proteins and viral load. In this same study, Env-proteins show a correlation between CTL 
responses and higher viral load. Pereyra et al., (2008) reported that HIV controllers (HIV 
infected patients without antiretroviral therapy for at least one year and plasma HIV-1 RNA is 
< 50 copies/ml by ultrasensitive PCR), preferentially target Gag over other viral proteins. Other 
studies also reported the superior in-vitro suppression of viral replication in autologous CD4+ 
T-cells using inhibition assays as mediated by Gag-specific rather than Nef or Env-specific 
CTL responses (Saez-Cirion et al., 2009, Julg et al., 2010, Ndhlovu et al., 2012). Taken 
together, these data suggest that among viral proteins, Gag-proteins are important for CTL 
mediating viral control.   
 
1.5.9 CTL Selection Pressure and Viral Escape 
 
The impact of CTL selection pressure is readily observed by sequencing autologous virus, 
which undergoes rapid immune-driven evolution in-vivo following acute infection (Walker and 
McMichael, 2012). Genome amplification techniques have shown clear evidence of CTL 
escape within 25-32 days of infection (Goonetilleke et al., 2009). Ultra-deep sequencing has 
also revealed that the virus explores multiple pathways to escape CTL pressure (Fischer et al., 
2010). The pathways to immune escape appear limited, as shown by studies of genetically 
identical twins infected by the same virus strain, in whom the earliest targeted epitopes and 
escape variants were similar (Draenert et al., 2006). 
Escape from CTL responses can occur through multiple mechanisms; mutation within 
CTL-epitopes can clearly impact processing and subsequent recognition (Draenert et al., 
2004b, Le Gall et al., 2007, Tenzer et al., 2009). Mutations in the TCR contact residues have a 
variable impact on CTL recognition, and the ability to cross-recognize variants appears to be 
influenced by thymic selection (Kosmrlj et al., 2010). HLA alleles associated with better 
outcome following HIV infection are associated with presentation of fewer self-peptides in the 
thymus, resulting in a repertoire in which more clones survive negative selection, and are more 




together, these studies give insight to the association between HLA alleles and HIV infection 
outcome. 
 
1.6 Human Leukocyte Antigen (HLA) 
 
The major histocompatibility complex (MHC) coding region, known as HLA in human and 
located on the short arm of chromosome 6, is the most polymorphic of the entire human genome 
(Goulder and Watkins, 2008, Goulder and Walker, 2012). Functional MHC molecules are 
made of a heavy (α) chain and a β2-microglobulin chain genes encoding class I loci (Sidney et 
al., 2008). Peptide binding by MHC class I molecule is accomplished by interaction of the 
peptide amino acid side chains with discrete pockets within the peptide-binding groove of the 
MHC molecule formed by the α1 and α2 domain of the heavy chain, (Figure 10), (Sidney et 
al., 2008). The main binding energy of peptide to the class I HLA molecule is provided by the 
interaction of residues in position 2 and the C-terminus of the peptide with the B and F binding 
pockets respectively, (Figure 11), (Madden, 1995).  
 
            
Figure 10: Schematic Representation of 
HLA Molecule Housing a Peptide. The 
peptide (blue) is the amino acid sequence 
sitting in the peptide binding pocket of 






Of the three MHC class I loci in humans (HLA-A, HLA-B and HLA-C), HLA-B is the most 
polymorphic, with 817 different HLA-B molecules described, compared to 486 distinct HLA-
A and 263 distinct HLA-C molecules (Mungall et al., 2003). The polymorphism of HLA 
molecules influences the peptide-binding repertoire. However, multiple class I HLA alleles can 
bind identical peptides due to the similarity in their peptide binding motifs. HLA alleles sharing 




(Sette and Sidney, 1999). Polymorphism of class I HLA molecules have been shown to 
contribute to differences in disease outcome (Goulder and Watkins, 2008).  
 
Figure 11: Interactions between 
HLA Molecules and Peptides. 
Panel A illustrate examples of 
peptide motifs. The listed amino 
acids as well as many others have 
been found to complex with the 
respective HLA class I molecules. 
The anchor residues are 
highlighted in yellow. Panel B is a 
longitudinal section through the 
peptide-binding groove of pocket 
A to F. Pocket B and F bind the 
peptide residue P2 and P9 
respectively. Some of the peptide 
residues pointing into the HLA molecule have a greater influence over binding while the 
residues that point outward affect the T-cell receptor recognition (Klein and Sato, 2000). 
 
1.6.1 Class I HLA Supertype 
 
The peptide repertoire of a specific molecule is to a large extent determined by the molecular 
structure accommodating the main anchor positions of the presented peptide (Sidney et al., 
2008). Multiple class I HLA alleles can recognize common peptides due to the homology of 
amino acids within the anchor positions of the presented peptides (Sette and Sidney, 1998). 
Examples; A2 supertype share specificity for peptides with aliphatic hydrophobic residues in 
position 2 and at the C-terminus. A3 supertype recognize peptides with small or aliphatic 





Figure 12: Supertype Classification of HLA-B Alleles. The alleles associated with each 
HLA-B supertype, multiple supertype, or those that are unclassified, are shown. Under each 
supertype, alleles are grouped by colour on the basis of the stringency of selection: 
experimentally established motif (i.e., reference panel) light green: exact match(es) in the B 
and F pockets, white: one exact and one key residue pocket match, yellow: key residue 
match(es) at B and F pockets. Alleles with no match at one or both pockets are listed with red 




Overlapping peptide with distinct binding pocket have been demonstrated among class I HLA-
B supertype (Sidney et al., 1995, Sidney et al., 1996b). A study illustrated that proline is 
preferably selected at position 2 (anchor-motif) by HLA-B7 supertype (Leslie et al., 2006a). 
Another study showed that  HLA-B*27 binds peptides with arginine at position 2 and HLA-
B*57 binds peptides with a tryptophan at the C-terminus (Marsh et al., 1999). There are nine 
HLA supertypes that have been well described based on their structural similarities and the 
overlapping peptide-binding motifs (Sette and Sidney, 1999). Each of these supertypes allows 
coverage of about 35-55% of the general population irrespective of ethnicity (Sidney et al., 
1996a), 83-89% coverage could be achieved when 3 of the supertypes are combined (Sette and 
Sidney, 1998). These analysis suggest that an effective, non-ethnically biased HIV CTL based 
vaccine design is feasible. 
 
1.6.2 The B57 Supertype 
 
The most reproducible class I HLA association with low HIV viremia and prolonged AIDS-
free survival has been observed with HLA-B*57 and related HLA alleles (Kaslow et al., 1996, 
Keet et al., 1999, Hendel et al., 1999, Trachtenberg et al., 2003). Nearly all HLA-B*57 alleles 
are characterized by unique valine at position 97, which contribute to the formation of the C-
pocket of the class I antigen-binding cleft (Lardy et al., 1998). HLA-B*58 also belongs to the 
B57 supertype both by structural and functional similarities. Other alleles within HLA-B*57 
supertypes are; B*57:01, B*57:02, B*58:01, B*58:02, B*15:16, and B*15:17 (Figure 12) 
(Sette and Sidney, 1999). These alleles share a preference for antigen supermotifs with small 
aliphatic residues in position 2 and aromatic or hydrophobic residues at the C-terminus of their 
peptide ligands (Sette and Sidney, 1999). The B57 supertype alleles have a combined 
phenotypic frequency of some 10-25% in Caucasoid and African populations (Sette and 
Sidney, 1999). In addition, HLA-B*57:01 in Caucasoids and HLA-B*57:03 in Africans 
demonstrate broad functional cross-reactivity to both common and rare variants of a dominant 
p24 epitope (Gillespie et al., 2002). These studies further suggest that broad based vaccine that 








1.6.3 The B07 Supertype 
 
Human leukocyte antigen-B*42:01, B*81:01, B*39:10, B*35:01, B*07:02, fall into the HLA-
B07 supertype, (Figure 13), (Sidney et al., 2008). Alleles in this supertype harbour a proline in 
the B pocket and an aromatic, aliphatic and hydrophobic residue in the F pocket (Sidney et al., 
2008). The B07 supertype in Caucasoids and African Americans population infected with HIV 
subtype B is associated with high viremia, relatively poor responses and fast progression to 
AIDS (Pereyra et al., 2010). In contrast, in African populations infected with HIV subtype C, 
it is associated with low viremia (Matthews et al., 2008, Leslie et al., 2010). A study by Leslie 
and colleagues in 2006 that sought to address the role of HLA-B07 supertype in the immune 
control of clade C HIV, using a large cohort of clade C infected patients of Zulu/Xhosa ethnic 
origin from KwaZulu-Natal, South Africa, showed the promiscuity of epitopes restricted by 
the alleles within this supertype (Leslie et al., 2006a). However, the assay used in this study 
has been shown not to correlate with the responses of CTL to the restricted epitopes in-vivo 
(Bennett et al., 2008). Therefore, there is need for the development of functional assay that can 
inform on the direct correlate of CTL responses in-vivo when presented with promiscuous 
epitope restricted by alleles within the same supertype.   
 
1.6.4 Immunodominant Epitopes Restricted by Alleles within B57 Supertype 
 
Strong HIV-specific CTLs responses targeting multiple epitopes in the conserved p24 region 
of Gag protein are likely to contribute to viral control (Scherer et al., 2004, Altfeld et al., 2006, 
Kiepiela et al., 2007). Alleles within B57 supertype restrict multiple HIV peptides with 
predominant responses by HIV-specific CTL against Gag (Goulder et al., 1996, Klein et al., 
1998). A study in South African HIV infected population showed that targeting epitopes within 
the Gag protein, especially those restricted by B57 could increase the expected time to AIDS 
from 2-3 years after infection to ˃8-10 year (Kiepiela et al., 2007). In the study, HLA-B*57:03 
and HLA-B*58:01 were shown to be the most prevalent alleles within the B57 supertype. HLA-
B*57:03 showed a dominant response to KAFSPEVIPMF (Gag residue 162-172), while HLA-
B*58:01 restricted immunodominant response is against TSTLQEQIAW (Gag residue 240-
249). ISPRTLNAW (Gag residue 147-155) is also a well characterised p24 Gag 
immunodominant epitope restricted by most alleles within B57 supertype (Goulder et al., 
1996). Although HLA-B57 is comprised of “protective” alleles, not all HIV infected patients 




reason for the differences observed within HLA-B57 alleles could be the apparent small 
differences (micropolymorphisms) existing between these alleles (Kloverpris et al., 2012b).  
Mutations at specific positions of HIV-Gag peptides occur frequently and are unique to 
HLA-B57 and -B58 positively individuals that are infected with HIV clade B and C  (Leslie et 
al., 2004). The gradual accumulation of mutations within the restricted immunodominant HIV-
Gag peptides can result into functional loss of T-cell recognition (Yang et al., 2003). This 
indicates that positive selection for these mutations is being driven by CTL specific for the 
restricted epitope. However, the extent to which HIV-specific CTL can recognise and kill 
infected targeted cells restricting wildtype and variant epitopes is unknown.  
 
1.6.5 Immunodominant Epitopes Restricted by B07 Supertype 
 
The most common B07 supertype class I HLA alleles in the Zulu/Xhosa population of South 
Africa are HLA-B42:01, B81:01, and B07:02, which occur at phenotypic frequencies of 18.6, 
9.6 and 8.2%, respectively (Leslie et al., 2006a). These alleles are closely related, with no 
amino acid differences in the residues forming their B and F primary binding pockets. Clade C 
p24-TL9 (TPQDLNTML, Gag residue 180-186) is restricted by majority of the class I HLA 
alleles within B07 supertype. Leslie et al., (2006a) showed that there is a significant greater 
variation in HIV-specific CTL response to TL9-Gag in individuals expressing each of the 
alleles within B07 supertype, with HLA-B81:01 having a higher CTL response than other 
alleles. Although TL9 is a dominant epitope restricted by HLA-B81:01, B42:01 and B39:01, 
there were striking differences in the frequency of polymorphism between these alleles, which 
could invariably have profound impact on T-cell immunity (Gao et al., 2001a, Geldmacher et 
al., 2009, Goulder and Walker, 2012, Kloverpris et al., 2012a, Kloverpris et al., 2012b) The 
impact of these differences observed within class I HLA molecules restricting identical 
epitopes on CTL was investigated in our study.   
 
1.7 Class I HLA Molecules and Disease Outcome 
 
Class I HLA alleles bind peptide fragments derived from the intracellular pathogens and 
present them to CTLs (Figure 8), thereby initiating cytotoxic T-cell responses. The fragmented 
peptides are loaded into the peptide-binding groove of the HLA molecules and transported to 




been identified consistently to have significant impact on the rate of disease progression 
(Kaslow et al., 1996, Hendel et al., 1999, Migueles et al., 2000, Lazaryan et al., 2006).  
Class I HLA molecules and the peptides they present are significantly important 
(Goulder and Watkins, 2008), single amino-acid differences between closely related class I 
HLA alleles may have crucial consequences in the antiviral efficacy of CTL (Archbold et al., 
2009, Kloverpris et al., 2012b); examples include the association of HLA-B*35:02 and HLA-
B*35:03 with rapid disease progression and a lack of any such association for HLA-B*35:01, 
which differs from HLA-B*35:02 and HLA-B*35:03 by only three and one amino acid 
respectively (Steinle et al., 1995, Gao et al., 2001a). These small changes would be expected 
to affect the binding of the C-terminal amino acid of the F pocket of the HLA molecule (Smith 
et al., 1996).  
Study on HIV infection showed a strong association between HLA-B*58:01 and low 
viral load, whereas HLA-B*58:02, which differs from HLA-B*58:01 by three amino acids, 
was associated with high viral load (Table 1), (Kiepiela et al., 2004a). Another study of four 
closely related HLA alleles within the B7 supertype (B*07:01, B*42:01, B*39:02, B*81:01) 
demonstrated that, even when identical peptides are presented by these closely related alleles, 
different selection pressure on the virus could be observed (Leslie et al., 2006a). Hence, the 
existence of class I HLA polymorphism could be the reason for the differences in disease 
outcome observed within class 1 HLA alleles restricting identical epitopes and this could have 



















Table 1: Some of the Class I HLA-B Alleles, HIV Infection Outcome and their Restricted 
Epitopes (Goulder and Watkins, 2008). 
MHC class I allele Progression Viral setpoint Epitope restricted HIV protein 
HLA-B*13:02 Slow Low RQANFLGKI Gag 429-437 
HLA-B*18:01 Rapid  High RQANFLGKI Gag 429-437 
HLA-B*27:05 Slow Low KRWIILGLNK Gag 263-272 
HLA-B*35:02 
HLA-B*35:03 
Rapid High KRWIILGLNK Gag 263-272 














HLA-B*58:02 Rapid High QTRVLAIERYL Gp41 577-587 




HLA-B*42:01 Rapid High TPQDLNTML Gag 180-188 
 
1.8 Measurement of HIV-specific CTL responses 
 
Despite the strong evidence of the important role CTL plays in the control of HIV infection, 
current assays to  quantify T cell immunity have failed to correlate HIV-specific CTL responses 
with protection from infection or control of viral replication (Addo et al., 2003, Frahm et al., 
2004). The rapid recognition and subsequent elimination of HIV infected cells before 
production of new viruses represent critical effector functions of HIV-specific CTL that are not 
reflected in the current assays (D'Souza and Altfeld). The merits and demerits of several assays 







1.8.1 Chromium Release Assay 
 
Chromium (51Cr) release assay (CRA) is the earliest method to detect HIV-specific CTLs (Sun 
et al., 2003). It is performed either on fresh cells by measuring CTL activity (Walker et al., 
1987, Plata et al., 1987), or on CTL lines by evaluating memory CTL reactivity (Nixon et al., 
1988). In CRA, class I MHC matched and mis-matched target cells expressing HIV antigen are 
labelled with radioactive 51Cr and incubated with HIV-specific CTL for 4-6 hours. CTL killing 
is measured indirectly by detecting 51Cr released by dying target cells into the supernatant 
(Shacklett, 2002).  
Although CRA is useful in the identification of optimal epitopes recognized by CTL, it 
requires large numbers of PBMC, uses radioactive material, and is time consuming. More 
importantly, it may introduce a bias in CTL analysis since the cells which easily expand in-
vitro are mainly memory T-cells, while the CTLs which have proliferated in-vivo for many 





Enzyme-linked immunospot (ELISPOT) IFNγ assay; which is an adaptation of ELISA, is used 
to enumerate the function of CTL by quantifying the amount of IFNγ secreted when stimulated 
with peptide (Czerkinsky et al., 1988). Upon stimulation of CTL with exogenous peptide, CTL 
specific for the peptide secrets IFNγ and the secreted cytokine is captured on membrane coated 
by anti-cytokine monoclonal antibody (Streeck et al., 2009). Biotinylated polyclonal antibody 
specific for the secreted cytokine and alkaline-phosphatase conjugated with streptavidin are 
used to identify the blue-black colour formed at the spot of cytokine localization. The secreted 
IFNγ is viewed using a computerized camera that quantify cytokine secreted by CTL in 
response to antigen-specific stimulation (Nylander and Kalies, 1999).  
Despite the usefulness of ELISPOT to quantify CTL magnitude in response to 
stimulation with HIV peptide, ELISPOT assay usually relies on IFNγ as a functional readout 
and may therefore miss antigen-specific cells that do not produce IFNγ. In addition, ELISPOT 
has also been shown not to correlate with in-vivo virus control (Pantaleo and Koup, 2004, 






1.8.3 Tetramer Binding Assay 
 
Tetramer binding assay provides an elegant, sensitive means of quantifying antigen specific-
CTL frequency in a population of T-cells and is used in characterising immunodominant 
epitopes (Altman et al., 1996, Ogg et al., 1998). Tetramer binding assay include coupling of 
tetrameric complexes of MHC-class I with CTL population. The tetrameric complexes directly 
bind the T cell receptors of CTL specific for the tetrameric molecule and the tetramer specific 
CTL can be quantified using flow cytometry (Ogg et al., 1998). However, responses of CTL to 
well-characterized immunodomionant epitopes by tetramer binding assay overlooks the 
potential complexity of these responses (Shacklett, 2002), such as: capacity to secret cytokines 
and their ability to proliferate in response to stimulation with HIV peptides.  
 
1.8.4 Intracellular Cytokines Assay 
 
Antigen-specific stimulation, followed by inhibition of cytokines secretion and measurement 
of accumulated intracellular cytokines by flow cytometry is referred to as intracellular 
cytokines staining (ICS) (Shacklett, 2002). The produced cytokines are stained with their 
corresponding antibodies, followed by quantification using flow cytometry. ICS provides 
important insight into the dynamics of CTLs upon encountering their cognate antigens. ICS is 
sensitive and allow screening for responses against multiple CTLs’ epitopes in a single assay 
and require small number of PBMC.  
However, studies have shown that cytokines production by CTLs do not correlate with 
in-vivo control of HIV replication (Pantaleo et al., 1994, Yang et al., 1996, Valentine et al., 
2008, Gray et al., 2009), and did not predict the lack of efficacy in the vaccine trials 
(Buchbinder et al., 2008, McElrath et al., 2008). Therefore, as peptide based assays do not 
approximate the ability of CTL to suppress the replication of the virus in-vivo, novel assays 
that will represent the direct picture of CTL suppressive capacity of HIV replication in-vivo is 
needed. 
 
1.8.5 Viral Inhibition Assay (VIA) 
 
The viral inhibition assay (VIA) earlier demonstrated by Bennett et al. (2008), has been shown 
to be a suitable assay that reflects in-vivo CTL function. The VIA incorporates steps in viral 




generated viral peptides within targets cells. The assay readout is by quantifying HIV-p24 
released into the media through enzyme linked immunosorbent assay (ELISA). Although the 
ELISA-VIA can be used to quantify the antiviral activity of CTL against different clades of 
viruses, the assay is faced with some challenges such as: it is labour intensive, it requires the 
separation of CD4+ T-cells and CTLs and measurement of p24 over time, the cell-killing ability 
can vary with manipulation and culture of lymphocyte populations, in-vitro HIV replication 
can vary greatly and is dependent on input virus strain and cellular activation. (D'Souza and 
Altfeld).    
 
1.8.6 The Use of CEM-GFP Reporter T Cell Lines (GXR cell lines) as Target Cells in 
Viral Inhibition Assay 
 
The CEM-GFP reporter T cell line (GXR-cell line) was used as target cells to obtain the precise 
physiological correlate of the antiviral activity of HIV-specific CTL. The GXR-cell line was 
first described by Gervaix et al. (1997), and was further modified to be susceptible to both 
CXCR4 and CCR5 co-receptors by Brockman et al. (2006). The cell lines express green 
florescent protein in a tat-dependent manner upon HIV infection. In addition, it has been 
genetically engineered to over express specific class I HLA molecule.  
The GXR-VIA has advantages over the conventional ELISA-VIA such as: it is free of 
autologous virus, incubation period is reduced to 3 days instead of 7 days, and it also minimizes 
variations introduced by long term culture. Different GXR-cell lines were used as target cells 





1.9 Study Rationale 
 
Studies on HIV infection strongly suggest that HIV-specific CTL and the restricting class I 
HLA alleles play a critical role in immune control of HIV. CTLs recognize virus infected cells 
through antigenic viral peptide fragments of 8 to 12 amino acids in length, that are presented 
by class I HLA molecules. Class I HLA alleles bind specific virus derived peptide fragments. 
Interestingly, more recent studies have demonstrated that closely related class I alleles can 
present identical epitopes due to the homology of amino acids within the major binding pockets 
of the peptide binding cleft. However, the antiviral efficacy of HIV-specific CTL when 
identical epitopes are presented by closely related HLA alleles is unknown.  
Few studies have shown that class I HLA alleles can restrict promiscuous mutant 
epitopes, no study has shown the functional consequence of HIV-specific CTL when presented 





1.10 Aim of the Study 
 
The aim of the study is to conduct a systematic analysis of the viral inhibitory activity of HIV-
specific CTL targeting identical epitopes restricted by different closely related class I HLA 
alleles from the same supertype. 
 
1.10.1 Specific Objectives 
 
1. Validation of modified GXR viral inhibition assay with the standard viral inhibition 
assay using autologous activated CD4+ T-cells as target cells. 
 
2. To conduct a comparative analysis of viral inhibition activity of CTL which 
recognise identical epitopes restricted by different class I HLA alleles from the same 
supertype. 
 
3. Investigate whether class I HLA alleles belonging to the same supertype can 














CHAPTER TWO: Methodology 
 
2.1 Study Ethics Consideration 
 
This study was approved by the Biomedical Research Ethics Committee (BREC) of the 
University of KwaZulu-Natal and all study subjects gave written informed consent for 
immunology, genetics and virological studies. 
 
2.2 Study Subjects 
 
Subjects with chronic and acute untreated HIV-1 subtype C infection from Zulu/Xhosa ethnic 
origin were recruited from Sinikithemba (SK) clinic at McCord Hospital and Prince Mshiyeni 
(AS) Hospital, Durban, South Africa. Frozen peripheral blood mononuclear cells (PBMCs) 
samples from the subjects stored at vapour phase of liquid nitrogen were used to conduct this 
study.  
  
2.3 Inclusion Criteria 
 
The participants included in this study were patients with known HLA type; B7 supertype 
(B*81:01, B*42:01 alleles) and B57 supertype (B*57:03, B*58:01 alleles).  
 
2.4 HLA Typing 
 
HLA typing was performed on patients’ DNA samples at the Mary N. Carrington’s Laboratory, 
Centre for Cancer research, National Cancer Institute, Fredrick, USA, as previously described 
(Kiepiela et al., 2004b).  Briefly, DNA samples were first typed to an oligo-allelic level using 
Dynal RELITM reverse Sequence Specific Oligonucleotide (SSO) kits for the HLA-A, HLA-
B and HLA-C loci (Dynal Biotech). Refining the genotype to the allele level was performed 
using the Dynal Biotech Sequence-Specific priming (SSP) kits in conjunction with the previous 
SSO type. Where alleles were still not defined to the allele level, the sequence specific primer 







2.5 Separation, Counting and Cryo-preservation of PBMCs 
 
The blood was diluted with PBS (Whitehead scientific) in a 1:1 dilution. This was then layered 
very slowly over Histopaque 1077 using a Drummond pipette aid in a 1:1 dilution in a 50 ml 
tube. The tube was held at a 45º angle and the diluted blood was allowed to run down the side 
of the tube until the 40 ml mark was reached. The blood floated on top of the Histopaque. The 
tube was then centrifuged (Eppendorf 5810 AG) at 1,500 rpm for 30 minutes at room 
temperature. A pipette was used to aspirate off the opaque interface containing the 
mononuclear cells. The mononuclear cells were transferred to a second 50 ml tube. The tube 
was filled to 40 ml with PBS. The tube was centrifuged (Eppendorf 5810 AG) at 1,500 rpm for 
10 minutes at room temperature. The supernatant was poured off and the lymphocytes pellet 
was gently resuspended. Twenty ml of warm R10 medium was then added to the tube and the 
sample was incubated at 37 ºC in a CO2 incubator until it was ready to be counted. 
An aliquot of cell suspension was prepared for counting. Twenty µl cells was added to 
180 µl Guava counting solution (Merck, Germany) in a micro-centrifuge tube to produce a 1:10 
dilution. The mixture was incubated for 8 minutes in the dark before being acquired on the 
Guava counter (Merck) according to the manufacturer’s instructions. 
Incubated PBMCs were centrifuged (Eppendorf 5810 AG) at 1,500 rpm for 10 minutes 
at 4 ºC and the supernatant was discarded. The cell pellet was gently re-suspended using a 
pipette tip and all clumps were resolved. The tube was then transferred to an ice box containing 
crushed ice. Ten million cells were thoroughly mixed with 500 µl of fetal calf serum (FCS) 
(BioCom Technology, USA), freezing media (500 µl of FCS with 20% dimethyl sulfoxide 
(DMSO) (Merck, Germany)) were further added to the mixture in a drop-wise manner. The 
cells in freezing solution were then transferred to the cyovial and the cryovial was transferred 
into special containers called Mr. Frosty’s (Nalgene). The freezing containers were then placed 
into a -80 ºC freezer. The Mr Frosty’s contain iso-propanol and cool down the cells at a rate of 
1 ºC per minutes which is considered optimal for the cells quality. The vials were transferred 
from the Mr. Frosty’s to the vapour phase of liquid nitrogen freezer for long term storage after 








2.6 Thawing of the Cryo-preserved Cells 
 
Cells were rapidly thawed at 37 ºC in the water bath until only a silver of ice remained. The 
outside of the cryo-tube was swabbed with 70% ethanol before the cells were transferred to the 
15 ml tube containing 9 ml of warm R10. The tube was centrifuged (Eppendorf 5810 AG) at 
1,800 rpm for 6 minutes. The supernatant was discarded, ensuring that maximum amount of 
the media was removed because of the freezing solution that contained dimethyl sulfoxide 
(DMSO) (Merck) which is toxic to the cells. The pellet was then resuspended with 20 µl of 
DNAse (Roche, USA) to disintegrate clumpy cells, 10 ml of R10 was further added and 
centrifuge at 1,800 rpm for 6 minutes. The cells were then resuspended in R10 medium, rested 
for 2 hours, thereafter counted manually. Cells were counted manually by adding 10 µl of the 
suspended cells to 90 µl of trypan blue. Ten µl of the mixture were pipetted on the 
haemocytometer (HYCOR Biomedical, USA), and counted using Olympus CH20 microscope 
(Olympus Optical, Japan). The count was multiplied by the dilution factor and by 104 and 
reported as the number of cells per l ml of media. 
 
2.7 Viral Inhibition Assay (VIA) 
2.7.1 Principle 
 
Target cell is infected with HIV. An enzyme proteasome in the infected cell helps in the 
intracellular degradation of the HIV peptides. Transport associated protein (TAP) transfer the 
degraded peptides into the endoplasmic reticulum; where class I HLA molecule binds to the 
cognate peptide and transport it to the cell surface for presentation to CTL. T-cell receptor of 
the CTL recognizes the presented foreign antigenic peptide and trigger the release of effector 
molecules in the CTL. The effector molecules are directly release on the infected target cell, 




The various components of VIA are: generation of HIV stocks, Preparation of target and 






2.7.2.1 Generation of HIV Stock 
 
Integrated plasmid with all the HIV genomic regions and the GXR cells were obtained from 
Dr. Jacklyn Mann, HPP, Durban, South Africa. The plasmid was used to transfect GXR cells. 
Four million GXR cells were electroporated (Genepulser II Capitance, Biorad) using 5 µg of 
the NL4-3 plasmid at 250 Volts, and 950 µF for 10 seconds. The electroporated cells were 
transferred to T25 flask containing 1 million GXR cells suspended in 9 ml of R10 and 4 µl of 
polybrene (Sigma, USA). The polybrene was added to soften the GXR cells walls for easy 
penetration of the viral particles into the cells. The cells were cultured for 8 days by removing 
and adding 2 ml of fresh media. The percentage infectivity was monitored using LSRII (BD, 
Germany). At approximately 30% infection, the virus were harvested and cryo-preserved. 
   
2.7.2.2 Harvesting and Cryo-preservation of the Generated Virus Stocks 
 
The infected cultured containing the generated virus was transferred to 50 ml tube and 
centrifuged (Eppendorf 5810 AG) at 1,800 rpm, 4 ºC for 6 minutes. The virus-containing 
supernatant was aspirated, aliquoted in labelled cryovials and stored at -80 ºC until use.  
 
2.7.2.3 Generation of Recombinant Virus Stock 
 
Patient derived first round PCR product harbouring Q182S mutation within the Gag region was 
obtained from Dr. Michelle Gordon, HPP, Durban, South Africa. Second round PCR was 
carried out by Miss Avashna Singh as previously described by (Wright et al., 2010). 
The subtype B pNL4-3∆gag-protease backbone stock, containing a BstE II restriction 
enzyme site in place of the viral gag-protease coding region, was obtained from Dr. Jacklyn 
Mann, HPP, Durban, South Africa. To amplify pNL4-3∆gag-protease stock, Luria-Bertani 
(LB) broth (Sigma, St Louis, USA) containing 100 µg/ml ampicillin was inoculated with 17.5 
µl STBL3 stock containing pNL4-3∆gag-protease per 100 ml of LB broth and incubated 
overnight at 37 ºC in a shaking incubator (INFORS HT, Bottmingen, Switzerland). The plasmid 
was then purified using the plasmid Maxi kit (Qiagen), quantified using a Nano-drop 
spectrophotometer (Thermo Scientific, Delaware, USA) and stored in a -80 ºC ultrafreezer 
(Snijders Scientific, Holland) until use.  
GXR cells were co-transfected with the mutant amplified patient’s gag-protease and the 




sample) was digested with BstE II enzyme (Promega, Madison, USA) for 2 hours at 60 ºC in a 
water-bath to linearize the plasmid at the site of gag-protease deletion and allow for insertion 
of mutant amplified patients derived gag-protease by recombination. Recombination of gag-
protease with pNL4-3∆gag-protease was made possible by the use of long primers exactly 
complementary to NL4-3 on either side of gag-protease to generate gag-protease PCR product. 
During the BstE II digestion of pNL4-3∆gag-protease, the GXR cells were counted and 
the required number of cells was removed, pelleted and resuspended in fresh R10 medium. 
Four million cells per samples were suspended in 300 µl of R10 and transferred into 4 mm 
cuvettes (Biorad, USA). Ten µg of BstE II-digested pNL4-3∆gag-protease and 90 µl of 
patient’s gag-protease PCR product was transferred into the cuvettes containing the GXR cells 
and electroporated at 250 V and 950 µF (Genepulser II Capitance, Biorad). As a negative 
control, GXR cells were electroporated with pNL4-3∆gag-protease only. Electroporation 
allows for the temporary disruption of cell membranes, allowing uptake of molecules and is a 
techniques used to transfect cells with DNA (Spencer, 1991). Following 1-hour incubation at 
room temperature to allow for cell recovery, electroporated GXR cells were gently transferred 
to T25 flasks containing 1 million GXR cells suspended in 9 ml of pre-warmed R10 and 4 µl 
(1 µg/µl) of polybrene and incubated at 37 ºC and 5% CO2. Five days later, 5 ml R10 medium 
was added to each flask followed by further incubation. 
Electroporated GXR cells were incubated for 12 days before virus production was 
monitored to allow time for recombination of gag-protease amplicons with the NL4-3∆gag-
protease plasmid, followed by viral transcription, translation, particle production and spread in 
the culture. The percentage of the infected cells was monitored using LSRII (BD). At 
approximately 30% infection, the virus were harvested and cryo-preserved as described above.  
 
2.7.2.4 Sequencing and Titration of the Virus Stocks 
 
To confirm the presence of mutation under investigation in the harvested virus stock, the 
generated recombinant stock was sequenced. Virus stock was titrated to determine stock’s 
concentration. One million GXR cells were infected with 400 µl of each of the stock for 8 
hours. Thereafter, the infected cells were washed and 100, 000 cells per well were plated in 
duplicate in a 96-well plate and incubated for 3 days. An aliquot of 100, 000 uninfected GXR 
cells per well were also plated in duplicate alongside the infected cells as negative control. On 
day 3, incubated GXR cells were fixed and assessed the infectivity levels using LSRII (BD). 






2.7.2.5 Generation of CD4+ T Cells and CTLs 
2.7.2.5.1 Principle 
 
The CTLs were magnetically labelled with CD8 microBeads (Miltenyi Biotec). The suspended 
cells were loaded onto a calibrated MACS Column, which was placed in the magnetic field of 
a MACS separator. The magnetically labelled CTLs were retained within the column. The 
unlabelled cells (majorly CD4+ T cells) ran through; CD4+ T cells fraction was thus depleted 
of CTLs. After removing the column from the magnetic field, the magnetically retained CTLs 
were eluted as the positive selected cell fraction.  
 
2.7.2.5.2 Procedure 
2.7.2.5.2.1 Preparation of Reagents for CD4+ T Cells and CTLs Isolation 
  
Bovine Saline Albumin (BSA) (Whitehead Scientific) solution was used to prepare MACs 
buffer, which was used in the depletion experiment. To prepare BSA solution, 10g of BSA 
concentrate was added to 100 ml of distilled water and placed in the refrigerator (4 ºC) for 24 
hours to dissolve. MACs buffer was prepared by adding 49 ml of PBS (Whitehead Scientific) 
to 1 ml of BSA solution and placed on ice. R10/50 was also prepared by adding 25 µl of 
interleukine-2 (IL-2) to 50 ml of R10 and kept on ice until used. 
 
2.7.2.5.2.2 Separation of CD4+ T Cells and CTLs   
 
LS column (MACS Miltenyi Biotec GmbH, Germany) and CD8 MicroBeads human (MACS 
Miltenyi Biotec GmbH, Germany) was used to isolate CTLs and CD4+ T cells from PBMCs. 
The PBMCs were counted to know the volume of CD8 microBeads that would be needed for 
the isolation step. Cells were centrifuged at 1,800 rpm (Eppendorf 5810 AG) for 6 minutes at 
4 ºC and the supernatant was aspirated. The cells were resuspended in MACs buffer and wash. 
The supernatant was aspirated completely and 20 µl of CD8 MicroBeads was used per 107 
cells. The cells were mixed with the CD8 MicroBeads and incubated for 15 minutes at 4 ºC. 




centrifuging at 1,800 rpm for 6 minutes at 4 ºC. Supernatant was aspirated and the cells were 
resuspended in 500 µl of MACs buffer.  
The MS column was placed in the magnetic field and column was calibrated using 1 
ml of MACs buffer. Thereafter, the suspended cells were added to the column. The unlabelled 
cells fraction; which contained majorly the CD4+ T-cells were collected in a new 15 ml tube 
and 3 ml of MACs buffer was further added to the column. The total effluent was passed 
through the column twice to ensure maximum separation of CTLs from the CD4+ T-cells. 
The column was removed from the magnetic field and placed on a new 15 ml tube. Five ml of 
MACs buffer was dispensed into the column and plunged to release all the bounded CTLs.   
 
2.7.2.5.2.3 Purity of CD4+ T Cells and CTLs 
 
Purity of the CD4+ T cells and CTLs was determined by performing cell surface staining on 
the isolated fractions. Cells surface staining was carried out on the aliquoted PBMCs (before 
depletion), depleted CTLs and the enriched CTLs.  
Cells were placed in labelled FACs tubes and washed by centrifugation at 1,800 rpm 
(Eppendorf 5810 AG) for 6 minutes. The supernatants were aspirated and cells were suspended 
in 40 µl of 2% FCS/PBS, 0.1 µl of dead cells aqua-dye and incubated at room temperature in 
the dark for 10 minutes. After incubation, 200 µl of 2% FCS/PBS was added to each FACs 
tube containing the cells and centrifuged at 1,800 rpm for 6 minutes. The supernatant was 
aspirated and 34 µl of 2% FCS/PBS and 2 µl each of CD3 (Alexa fluor 647), CD4 (Alexa fluor 
700), and CD8 (CD8-PE) –antibodies (BD, Pharmingen) were added to each of the tubes and 
further incubated for 20 minutes. Thereafter, 200 µl of 2% FCS/PBS was added to each of the 
FACs tube to wash the cells. The supernatants were aspirated and each tube containing the 




Enzyme linked-immunosorbent viral inhibition assay (ELISA- VIA) is an inhibitory assay that 
determine the inhibitory capacity of CTLs by the quantification of p24 antigen through ELISA. 
The target CD4+ T cells were activated by culturing in R10/50 media and 0.1 µl (0.5µg/ml) of 
CD3 CD8-bispecific monoclonal antibody per 1 million cells for 3 days. The CTLs were rested 




On day 3, activated CD4+ T cells were counted, an aliquot of CD4+ T cells was set aside as 
negative control for the assay. The rest of the activated CD4+ T cells were infected at a 
multiplicity of infection (MOI) of 0.1 with the generated wild type NL4-3 virus for 4 hours at 
37 ºC. After 4 hours infection, cells were washed twice, counted and resuspended in appropriate 
amount of R10/50 to make up 1 million cells per 1 ml of media. Uninfected, infected (positive 
control) and infected (for bulk culturing) target cells were plated in triplicate at 105 cells per 
well in a 96-well plate. Resting CTLs were washed, counted and resuspended in appropriate 
amount of R10/50 media to make 1 million cells per 1 ml of R10/50 media. 
To assess inhibition, CTLs were added to the plated infected CD4+ T cells at a ratios 
of 1:1, 1:2 and 1:4. At day 3, 5 and 7, the co-cultures were fed by removing and adding 90 µl 
of R10/50. HIV in the removed supernatant were inactivated by the addition of 10 µl of triton 
(PerkinElmer, Boston, MA) to 90 µl of the supernatant containing virus. The harvested 
supernatants were cryopreserved at -80 ºC for p24 quantification using PerkinElmer ELISA-
kit (PerkinElmer, Boston, MA).  
 
2.7.2.6.1 PerkinElmer ELISA 
2.7.2.6.2 Principle 
 
Harvested supernatants were transferred to microplate wells which were coated with a highly 
specific mouse monoclonal antibody for HIV-p24. The immobilized monoclonal antibody 
captured the free HIV-p24 that have been released by the infected cells. The captured antigen 
was complexed with biotinylated polyclonal antibody to HIV-p24, followed by a streptavidin-
HRP (horseradish peroxidase) conjugate. The resulting complex was detected by incubation 
with ortho-phenylenediamine-HCl (OPD) which produces a yellow colour that was directly 
proportional to the amount of HIV-p24 captured. The absorbance of each coated plate was 
determined using a microplate reader (Promega, USA), and calibrated against the absorbance 
of an HIV-p24 antigen standard curve.  
 
2.7.2.6.2.1 Procedure  
 
The inhibitory activity of CTLs was assessed by quantification of HIV-p24 production in the 
harvested supernatants on day 3, 5 and 7. Serial dilutions of the harvested supernatants were 
made to reduce the concentration of HIV-p24 down to 1-400 pg/ml. The positive control was 




accordingly into the wells coated with HIV-p24 antigen. Diluted samples were also loaded into 
the 96-well plate and incubated for 2 hours at 37 ºC. Thereafter, 200 µl of the washing buffer 
provided by the kit manufacturer was dispensed into each of the well, washed 6 times and 
blotted. Detector antibody was measured based on the number of the tested wells, 200 µl was 
added to each well and incubated for 1 hour at 37 ºC. Washing step was repeated. Diluted 
streptavidin-HRP was added at 100 µl per well and incubated in the dark for 30 minutes at 37 
ºC. Washing step was repeated. Ortho-phenylenediamine-HCl substrate was added at 100 µl 
per well and incubated at 37 ºC for 20 minutes. Thereafter, stopping solution was added at 100 
µl per well and the plate was read using a microplate reader (Promega, USA). 
CTLs mediated inhibition was first expressed as the log10 reduction in the quantification 
of HIV-p24 of day 7 infected target cells without CTLs minus infected target cells with CTLs. 





A CEM-GFP reporter T-cells (GXR cells) that were over expressing class I HLA were used as 
target cells in the GXR-VIA. The cell lines were genetically modified to express green 
fluorescence protein (GFP) in a Tat-dependent manner upon HIV infection. In GXR-VIA, 
Infected target GXR-cell line were co-cultured with CTLs. Reduction in the cells expressing 
GFP measured by flow cytometry was used as a read-out for the inhibitory capacity of CTLs.  
The GXR-cell lines over expressing class-I-HLA molecules were developed by Dr. 
Mark Brockman (Simon Fraser University, Burnaby, Canada), using leukaemia cells. The 
endogenous HLA molecules of these cells were downregulated, though still present at low 
levels. Genes of Class I HLA of interest were used to transduce the cell line using Puromycin 
(3 µg/ml). The cells expressing high HLA molecule of interested were selected using 100 µg/ml 
hygromycin and stained clones using CCR5 antibody clone (Pharmingen). Cells were later 
sorted using pan-HLA antibody (clone W6/32). Sorted GXR cell line were cultured in R10 
media. At log growth phase, cells were harvested and 10 million cells were frozen down per 
vial. 
The frozen GXR cell line were thawed using the protocol described in section 2.6, and 




appropriate amount needed for the assay was infected at MOI of 0.5. An aliquot of GXR cell 
line were set aside as negative control. Infected GXR cell line were incubated for 24 hours at 
37 ºC. After 24 hours incubation, infected and uninfected GXR cell line were washed twice 
with R10 medium and 100, 000 cells were plated per well in duplicate in a 96-well plate.  
The isolated CTLs were counted and co-cultured with the infected GXR cell line 
expressing class I HLA under investigation at different target to effector ratios as showed in 
table 2. The setup plate was incubated for 3 days at 37 ºC.  
On day 3, cells population were harvested by spinning down the plate at 2,000 rpm 
(Eppendorf 5810 AG) for 6 minutes. The pallets were fixed using 300 µl of paraformaldehyde 
and transferred into cluster tubes for flow cytometry interrogation.  
One hundred thousand events were acquired for each experimental setup condition. 
Cells were hierarchically gated on GXR cell line with the cultured CTLs, infected cells 
expressing GFP. It was expected that if the CTLs were inhibiting, they should recognise and 
kill the infected target cells presenting their cognate antigenic peptide, thereby reducing the 
population of cells in the GFP expressing gate. The formula used to determine the inhibitory 




















Table 2: GXR VIA Setup. The table shows the experimental setup of uninfected, infected 
GXR cells and the CTLs in GXR-VIA. 
         
 
2.8 Validation of GXR-VIA 
 
To validate GXR-VIA, CTLs from 8-HIV infected subjects were concurrently assessed using 
GXR-VIA and ELISA-VIA. The attribute of the GXR-VIA was evaluated by correlating the 
CTLs’ inhibitory values obtained using GXR-VIA with the ELISA-VIA.  
 
2.9 Comparison of the Inhibitory Activity of CTL Targeting Identical Epitopes Restricted 
by Different Class I HLA Molecules within the Same Supertype 
 
2.9.1 Expansion of HIV-Specific CTLs 
 
Cytotoxic T lymphocytes specific for the restricted identical epitopes under investigation were 
expanded from the whole PBMCs. Thawed PBMCs were rested for 2 hours in R10 media at 
37 ºC. Cells were counted and an aliquot of cells (500,000 cells) were set aside for tetramer 
staining to confirm the percentage of the interested specific CTL in the PBMCs’ population. 
Half of the rested cells were pulsed with 10 µl of 200 µg/ml peptide and incubated in a CO2 
incubator at 37 ºC for 3 hours. The other half were activated by suspension in R10/50 and 
incubated in a CO2 incubator at 37 ºC for 3 hours. Cells were then transferred to T25-flasks 
and R10/50 were added to makeup 1 million cells/ml of the media. Cells were then incubated 
at 37 ºC in a CO2 incubator for two weeks. Cells were fed with 2.5 ml R10/50 twice a week. 
Prior to cell sorting of specific CTLs, tetramer staining was setup to access the percentage of 





2.9.2 Tetramer Staining and Cell Sorting of Antigen-Specific CTLs 
2.9.2.1 Principle 
 
Tetrameric complexes of class I HLA molecule was used to stain CTLs directed against 
specific HIV-antigenic peptide. Tetramers were soluble oligomeric class I HLA molecules that 
bind to the TCR of the CTLs with high avidity. Tetramers were complexed with fluorochromes 
and cells were analyse on LSR II to identify the tetramer specific CTLs. Staining with tetramer 




Rested cells were first stained with 0.1 µl of blue viability dye (molecular probes invitrogen) 
and incubated in the dark for 10 minutes at room temperature. Thereafter, cells were washed 
with R10 and stained with 10 µl of class I HLA tetramer of interest and incubated in the dark 
for 30 minutes at room temperature. Wash step was repeated and cells were surface stained 
with 2 µl each of CD8-V500 (BD), CD3 AlexaFlour 647 (BD), CD4 AlexaFlour 700 (BD) 
antibodies and incubated in the dark for 20 minutes at room temperature. The cells were washed 
and suspended in the 200 µl of PBS for flow cytometry interrogation. 
The stained cells were acquired on an LSR II (BD) and analysed using flowjo version 
8.8.6. Cells were hierarchically gated on lymphocytes, dead cells and CD3+ T-cells, CD4+ T-
cells and CTLs and the distinct tetramer-specific CTLs were gated from the CTLs population. 
Expanded specific CTLs were isolated by tetramer cell sorting. Prior to sorting of tetramer 
positive cells, cells were prepared by surface staining the expanded cells using 20 µl of class I 
HLA tetramer and incubated for 30 minutes at room temperature in the dark, followed by 2 µl 
each of CD8-V500 (BD), CD3 AlexaFlour 647 (BD), CD4 AlexaFlour 700 (BD) antibodies 
and incubated for 20 minutes at room temperature in the dark. Thereafter, HIV-specific CTLs 
were sorted on cell sorter (BD FACSAria, Germany).  
GXR-VIA was setup to compare the inhibitory activity of the sorted CTLs targeting 
identical epitopes restricted by closely related class I HLA molecules. GXR cell lines 
expressing class I HLA molecules restricting identical epitopes were used as target cells in the 
assay. The different GXR cell lines were infected with the generated wildtype NL4-3 virus 
(objective 2), recombinant virus harbouring mutation of interest (objective 3). Sorted CTLs 
were co-cultured with the infected GXR cell lines and incubated at 37 ºC for 3 days. CTLs 




controls in the experiment and incubated for 3 days at 37 ºC. The assay setup for objective 2 
and 3 for each restricting cell line is illustrated in figure 13.  
 
 
Figure 13: Experimental setup for objective 2 and 3. The diagram illustrate how GXR-VIA 
is setup to address objective 2 and 3. Infected and uninfected GXR cell line were co-cultured 
with CTLs isolated from healthy donor as control. Experimental condition includes infected 
GXR cell line with the sorted HIV-specific CTLs. This condition was setup side by side for the 
two closely related class I HLA alleles GXR-cell lines restricting identical epitopes under 
investigation with the tested HIV-specific CTL.  
 
 
On day 3, cells population were harvested by spinning down the plate at 2,000 rpm for 
6 minutes at 37 ºC. The pallets were fixed using 300 µl of paraformaldehyde and transferred 
into cluster tubes for flow cytometry interrogation. The inhibitory capacity of the HIV-specific 
CTLs recognizing identical epitopes restricted by one class I HLA molecule as opposed the 











2.10 Data Analysis and Statistical Considerations 
 
All FCS data generated via flow cytometry were analysed using flowjo (version 9.0.2). All 
plotted graphs and statistical analysis were done using GraphPad Prism version 4.0. All tests 






CHAPTER THREE: Results 
 
3.1 Validation of GXR-VIA with the Gold Standard ELISA-VIA 
 
The viral inhibition assay (VIA) first described by (Bennett et al., 2008) has been shown to be 
a better option for identifying immune correlate of HIV-specific CTL. This assay involves 
infecting activated CD4+ T cells with HIV and co-culturing with CTLs. Thereafter, p24 antigen 
is measured over time using ELISA. ELISA-VIA has several advantages over ELISPOT and 
intracellular cytokine staining assays because it incorporates steps in viral entry, antigen 
processing and presentation and relies on the recognition of endogenously generated viral 
peptides within the target cells, as opposed to the loading of target cells with exogenous 
peptides at non-physiological concentrations. However, in its current format, the assay has 
several limitations including the fact that it is technically very challenging and labour intensive. 
ELISA-VIA requires separation of CD4+ T cells and CTLs and long term cells culturing. The 
autologous virus present in the target CD4+ T cells introduces biases to the p24 readout and 
the assay readout varies greatly because it is dependent on input virus strain and cellular 
activation. Furthermore, ELISA-VIA is very expensive. 
Therefore, to overcome these limitations, we developed a GXR-VIA. The assay uses 
CEM-GFP reporter T-cell line (GXR-cell line) that has been genetically engineered to over 
express specific class I HLA molecule and expresses GFP upon HIV infection. The assay is 
less labour intensive and cheap to perform. We evaluated the performance of GXR-VIA 
compared to the gold standard ELISA-VIA and obtained comparable results. 
 
3.2 GXR Cell Line Surface Staining of Class I HLA 
 
To ensure the GXR cell line used in our study had comparable levels of class I HLA expression, 
we surface stained each cell line with pan-class I HLA-ABC (clone W6/32) antibody 
(BioLegend) before and after infection. All the GXR cell lines used expressed high levels 





Figure 14: GXR Cell Lines Surface Staining for Class I HLA Molecules Expression. The 
flow data show the expression levels of class I HLA molecules before and after infection of 
different target GXR cell lines used in setting up GXR-VIA. (A) B*81:01 GXR cell line (B) 
B*42:01 GXR cell line (C) B*57:03 GXR cell line (D) B*58:01 GXR cell line.     
 
3.3 GXR Cell Line Gating Strategy 
 
The GXR cell lines used as target cells in the GXR-VIA express GFP upon HIV infection. 
Cells were gated on cell line, followed by cell line expressing GFP, (Figure 15). Reduction in 
the infected GXR cell line expressing GFP after co-culturing with CTL was used as readout to 
evaluate the CTL killing activity. 
 
 
Figure 15: Gating Strategy. Cells were 
gated on cell line, followed by the infected 
cell line expressing GFP. The uninfected gate 
shows target population with less cells 
expressing GFP (0.0882) and the infected gate 
shows the infected target population with 17% 







3.4 Purity of CD8+ T Cells and CD4+ T Cells 
 
Effector cells (CD8+ T cells) and target CD4+ T cells were isolated from the PBMC of 8 HIV 
infected subjects as described in the method section. The clinical characteristics of the assayed 
subjects are shown in Table 3. The percentage purity of the isolated CD8+ T cells and CD4+ 
T cells used to setup the two viral inhibition assays were routinely greater or equal to 93% and 
78% respectively, (Figure 16).   
 
 
Figure 16: Purification of CD8+ 
T cells and CD4+ T cells. The 
diagrams show the percentage 
purity of effector and target cells 
routinely used in setting up the 
viral inhibition assays. The 
percentage purity of CD8+ T cells 
were routinely ≥ 93% and the 
percentage purity of CD4+ T cells used as target cells in ELISA-VIA were routinely ≥ 78%. 
 

















Table 3: Clinical Characteristics of the Subjects used to Validate GXR-VIA 




Class I HLA-B 
HAART Subject B B 
SK-199-B24 609 371 13:02 57:03 No 
SK-318-B07   370 23600 07:02 57:03 No 
SK-113-B16 351 <40 14:01 81:01 No 
SK-358-B05 354 59200 08:01 57:03 No 
SK-358-B10 200 7690 08:01 57:03 Yes 
SK-081-B20 261 26727 13:02 81:01 No 
SK-200-B02 567 14360 14:01 81:01 No 
SK-421-B18 482 13356 15:03 58:01 No 
         
 
 
3.5 Quantification of CD8+ T Cells Inhibitory Activity using GXR-VIA and ELISA-VIA 
 
The GXR-VIA was compared with the gold standard ELISA-VIA. GXR-VIA and ELISA-VIA 
were concurrently setup using CD8+ T cells (CTLs) obtained from 8 HIV infected subjects, 
(Figure 17). GXR cell line and CD4+ T cells were respectively used as target cells in GXR-
VIA and ELISA-VIA. CTLs’ inhibition obtained using GXR-VIA and ELISA-VIA were 
converted to percentage inhibition and used in statistical analysis. The observed viral inhibitory 
results using GXR-VIA significantly correlated with the ELISA-VIA, (Figure 18). These data 





Figure 17: Representation of 
GXR-VIA and ELISA-VIA. The 
diagrams show the data for one of the 
assayed subjects: SK-200-B02. (A) 
GXR-VIA: Subjects’ CTLs were 
able to inhibit viral replication by 
killing the infected target GXR cell 
line. The estimated inhibition value 
was 67.4%. (B) ELISA-VIA: The red 
line is showing the infected 
population (Positive control), the 
black line is the uninfected CD4+ T cells and the blue line showed the co-cultured population 




Figure 18: Correlation between 
GXR-VIA and ELISA-VIA. 
Significant correlation was 
observed when GXR-VIA and 
ELISA-VIA were concurrently 
setup using CTLs obtained from 8 
HIV infected subjects. Spearman 
rank correlation was used to 










CHAPTER FOUR: Results 
 
4.1 Comparative Analysis of Viral Inhibitory Activity of CTL Targeting Identical 
Epitopes Restricted by Different Class I HLA Molecules within the Same HLA Supertype 
 
The diversity of HLA molecules is one of the major obstacles to the development CTL vaccine 
against HIV. Although studies have demonstrated that multiple class I HLA alleles can restrict 
identical epitopes due to the homology of amino acids within the major binding pockets of the 
peptide binding cleft (Sette and Sidney, 1999, Lund et al., 2004, Sidney et al., 2005, Sidney et 
al., 2008), it is not clear whether the identical epitopes restricted by closely related class I HLA 
alleles would induced functionally equivalent CTL responses. We therefore investigated the 
functional consequence of CTL targeting identical epitopes restricted by closely related class I 
HLA alleles using GXR-VIA.    
We first focussed on the CTL targeting TL9 epitope restricted by class I HLA-B*81:01 
or B*42:01 alleles within B7 supertype. TL9 Gag-epitope is an immunodominant epitope 
restricted by HLA-B*81:01, B*42:01 and B*0702 alleles (Leslie et al., 2006b). HLA-B alleles 
play a dominant role in the immune control of intracellular pathogens including HIV (Kiepiela 
et al., 2004b, Prugnolle et al., 2005), and B7 is the most prevalent HLA-B supertype (Sette and 
Sidney, 1999). HLA-B*81:01 and B*42:01 alleles are one of the most prevalent alleles within 
B7 supertype among the South Africans, worst affected with HIV pandemic (Kiepiela et al., 
2004b, Leslie et al., 2006b). 
We further investigated the inhibitory activity of CTL targeting identical IW9 Gag-
epitope restricted by HLA-B*57:03 or B*58:01 within B57 supertype. We focussed on these 
alleles because studies have shown that individuals expressing HLA-B*57:03 or B*58:01 
alleles mount an immunodominant responses to IW9 epitope during acute HIV infection 
(Altfeld et al., 2003, Altfeld et al., 2006, Crawford et al., 2009). HLA-B*57:03 and B*58:01 
alleles are associated with slow progression to AIDS (Lazaryan et al., 2006, Kiepiela et al., 
2007). In addition, HLA-B*57:03 and B*58:01 are prevalent among Sub-Saharan Africa 
population (Kiepiela et al., 2004b, Goulder and Walker, 2012, Prentice et al., 2013). 
We first assessed the inhibitory activity of CTL targeting identical TL9 epitopes 
restricted by HLA-B*81:01 or B*42:01 alleles. We then investigated the functional 
consequence of CTL when in-vivo occurring mutant (Q182S)-TL9 epitope is restricted by 
HLA-B*81:01 or B*42:01 alleles. Lastly, we compared the Inhibitory activity of CTL targeting 




4.2 Inhibitory Activity of CTL Targeting TL9 Epitope Presented by HLA-B*81:01 or 
B*42:01 alleles  
 
Four HIV infected subjects expressing B*81:01 and 4 subjects expressing B*42:01 were used 
to compare the inhibitory activity of CTL targeting TL9 epitope when presented by either 
HLA-B*81:01 or B*42:01 alleles. The clinical characteristics of these subjects are shown in 
table 4. TL9-specific CTL were assessed by tetramer staining. To increase the total number of 
TL9-specific CTL, PBMCs were cultured in the presence of TL9 peptide for 12 days as 
described in the method section. The specificity of the expanded cells was verified by tetramer 
staining, (Figure 19). The expanded TL9-specific CTL population was sorted using cell sorter 
(BD FACSAria, Germany). 
 
 
Figure 19: Expansion of TL9-specific CTL 
from one of the Studied Subjects. PBMCs 
were stimulated with exogenous TL9 peptide 
for 2 weeks to expand TL9-specific CTL. The 
percentages of TL9-specific CTL for this 
subject before and after expansion were 


















Table 4: Clinical Characteristics of the B7 supertype Studied Subjects 




Class I HLA-B 
HAART Subjects B B 
SK-200-B02 567 14360 14:01 81:01        No 
SK-316-B05 588 11200 82:02 81:01        No 
SK-293-B01 624 188000 13:02 81:01        No 
SK-416-B03 210 55200 15:18 81:01/81:02        No 
SK-437-B08 337 64200 57:02 42:01        No 
AS2-1034-B9 508 10874 45:01 42:01        No 
AS2-0016-B13 457 14171 15:10 42:01        No 
AS2-0483-B11 553 34671 15:03 42:01        No 
 
 
The sorted TL9-specific CTLs were used as effector cells in the GXR-VIA, using GXR cell 
line overexpressing HLA-B*81:01 or B*42:01 alleles as target cells. Percentage killing when 
CTL was co-cultured with HLA-B*81:01 infected target cell line was compared with the 
percentage killing when CTL was co-cultured with B*42:01 infected target cell line, (Figure 
20). Our results showed that CTL targeting TL9 epitope was able to inhibit viral replication 
when TL9 epitope was presented by B*81:01 or B*42:01 alleles. The percentage maximal 








Figure 20: Inhibitory Activity of CTL 
Targeting TL9 epitope Presented by 
B*81:01 or B*42:01 Alleles. The diagrams 
show inhibition mediated by CTL from 
B*42:01 subject when TL9 epitope was 
presented by B*81:01 or B*42:01 alleles. The 
positive control consists of the infected target 
cell line with CTL from healthy donor, while 
the experimental condition consist of the 
infected target cell line with the tested TL9-





Figure 21: Representation of Maximal Inhibitory Activity of CTL Targeting TL9 Epitope 
at Different Target to Effector Ratios. Inhibitory activity of CTL from B*42:01 subject when 
presented with TL9 epitope by B*81:01 or B*42:01 alleles at different target to effector ratios 






4.2.1 No Difference in the Inhibitory Activity of CTL Targeting Identical TL9 Epitopes 
Presented by B*81:01 or B*42:01 Alleles 
 
Cytotoxic-T-Lymphocyte from the 8 subjects described in table 4.1 were assayed to assess the 
inhibitory activity of CTL when presented with identical TL9 epitopes by HLA-B*81:01 or 
B*42:01 alleles. Interestingly, analysis showed no difference in the inhibitory capacity of CTL 
targeting identical TL9 epitopes presented by HLA-B*81:01 or B*42:01 alleles at different 
target to effector ratios (Figure 22). In summary, these data suggest that TL9-specific CTL 
from B*81:01 and B*42:01 subjects are able to mediate viral inhibition when TL9 epitope is 
presented by either B*81:01 or B*42:01 alleles. 
 
Figure 22: Comparison of the Inhibitory Capacity of CTL Targeting Wildtype TL9 
epitopes Presented by B*81:01 or B*42:01 Alleles. CTL from 8 subjects described in table 
4.1 were assessed for their inhibitory capacity when presented with TL9 epitope by 
B*81:01(Blue) or B*42:01(red) alleles. Inhibitory capacity of CTL is not statistically different 
when TL9 epitope is presented by B*81:01 or B*42:01 alleles. P-Values were estimated using 








4.3 Inhibitory Activity of TL9-specific CTL Presented with in-vivo occurring mutant 
(Q182S)-TL9 Epitope by HLA-B*81:01 or B*42:01 Alleles 
 
Mutant (Q182S)-TL9 epitope is one of the variant epitopes that is frequently selected by 
subjects expressing HLA-B*81:01 or B*42:01 (Leslie et al., 2006b, Ntale et al., 2012). We 
therefore assessed the functional consequence of CTL when in-vivo occurring mutant (Q182S)-
TL9 epitope is presented by HLA-B*81:01 or HLA-B*42:01 alleles.  
We first generated recombinant virus harbouring mutation Q182S within TL9 epitope 
as described in the method section, and assessed its infectivity. To confirm the presence of the 
mutation in the generated virus stock, sequence was aligned with HXB2 reference sequence 
and WT-NL4-3 (Figure 23).  
Target GXR cell lines were infected with the generated recombinant virus to measure 
the infectivity levels. Infectivity levels on day 3 and 5 were used to determine the relative 
percentages of maximal infection (Figure 24). Recombinant virus infectivity compared to the 
WT-NL4-3 virus was estimated for day 5. Calculated infectivity level of mutant Q182S 
recombinant was 49%, suggesting that recombinant virus harbouring Q182S mutation was able 




Figure 23: Sequence of Recombinant Virus Harbouring Q182S Mutation within the TL9 
epitope. The sequence on row 3 shows change in the amino acid with reference to the HXB2 
and WT-NL4-3 sequence. Glycine (Q) was changed to Serine (S) at position 182 within the 






Figure 24: Percentage Infectivity of the 
Generated Recombinant virus as 
Compared to Wild Type (WT) NL4-3. 
Green bars are showing the infectivity levels 
of the recombinant virus stock harbouring 
Q182S mutation compared to WT-NL4-3 




4.3.1 No Difference was Observed in the Inhibitory Capacity of TL9-specific CTL 
Presented with in-vivo occurring mutant (Q182S)-TL9 Epitope by B*81:01 or B*42:01 
Alleles 
 
TL9-specific CTL from the 8 subjects described in table 4 were then investigated for their 
functional consequences when presented with mutant (Q182S)-TL9 epitope. Interestingly, our 
data showed that TL9-specific CTL were able to inhibit viral replication in both B*81:01 or 
B*42:01 infected target cell lines presenting mutant (Q182S)-TL9 epitope, (Figure 25).  
Estimated percentage maximal inhibition at different target to effector ratios for one of the 
subjects is shown in figure 26.  
Statistical analysis showed no difference in viral inhibitory activity of TL9-specific 
CTL presented with mutant (Q182S)-TL9 epitope by B*81:01 or B*42:01 alleles, even at low 
target to effector ratio (Figure 27). These data suggest that TL9-specific CTL from B*81:01 
and B*42:01 subjects are capable of recognizing mutant (Q182S)-TL9 epitope when presented 






Figure 25: Inhibitory Activity of TL9-
specifc CTL when Presented with mutant 
(Q182S)-TL9 Epitope by B*81:01 or 
B*42:01 Alleles. The flow data show TL9-
specific CTL from B*42:01 subject 
mediating killing of infected target cells 
presenting mutant (Q182S)-TL9 epitope in 








Figure 26: Maximal Inhibitory Activity of TL9-Specific CTL Presented with mutant 
(Q182S)-TL9 Epitope by B*81:01 or B*42:01 Alleles. Inhibitory activity at different target 





Figure 27: Comparison of the Inhibitory Activity of TL9-Specific CTL when mutant 
(Q182)-TL9 Epitope is Presented by B*81:01 or B*42:01 Alleles. TL9-specific CTL from 
the 8 subjects described in table 4.1 were assessed for their inhibitory capacity when presented 
with in-vivo occurring mutant (Q182S)-TL9 epitope. No difference was observed in the 
inhibitory capacity of the TL9-specific CTL presented with mutant (Q182S)-TL9 epitope 
presented by HLA-B*81:01 (blue) or B*42:01 (red) alleles at different target to effector ratios. 
All p-Values were estimated using paired t test. 
 
4.4. Inhibitory Activity of CTL Targeting IW9 Epitope Presented by HLA-B*57:03 or 
B*58:01 Alleles  
 
Reponses to p24 Gag IW9 epitope have been frequently associated with B*57:03 and B*58:01 
alleles expressing subjects (Matthews et al., 2008). We compare the inhibitory activity of CTL 
when presented with IW9 epitope by B*57:03 or B*58:01 alleles. We were able to expand 
IW9-specific CTL from 4 HIV infected subjects expressing HLA-B*57:03 allele. The clinical 
characteristics of the 4 subjects are shown in table 5. We tested the inhibitory activity of IW9-
specific CTL when the epitope was presented by HLA-B*57:03 or B*58:01 alleles. 
Our data showed that B*57:03 CTLs targeting IW9 epitope presented by B*57:03 or 
B*58:01 alleles were able to inhibit viral replication in both target cell lines, (Figure 28). The 






Table 5: Clinical Characteristics of the B57 Supertype assayed Subjects 




Class I HLA-B 
HAART     Subjects B B 
SK-420-B11 455 688 15:03 57:03         No 
AS2-0945-B4 912 1319 15:10 57:03         No 
SK-215-B08 480 34800 0702 57:03         No 




Figure 28: Inhibitory Activity of B*57:03 
CTL Targeting IW9 Epitope. The 
diagrams show the inhibitory activity of one 
of the studied subjects’ CTL presented with 
IW9 epitope by B*57:03 or B*58:01 alleles. 
B*57:03 CTL was able to recognise IW9 
epitope presented in the context of B*57:03 
or B*58:01 alleles and kill the infected cells 







Figure 29: Maximal Inhibitory 
Activity of B*57:03 CTL 
Targeting IW9 Epitope. The 
Graph shows the Inhibition of 
B*57:03 CTL when B*57:03 or 
B*58:01 alleles presents IW9 





Inhibitory activity of HLA-B*57:03 CTL was compared when B*57:03 or B*58:01 alleles 
present IW9 epitope. No difference was observed in the inhibitory activity of CTL targeting 
IW9 epitope presented by B*57:03 and B*58:01 alleles (Figure 30). Notably, a trend towards 
significance was observed at target to effector ratio 1:1. In summary, this data suggests that 
B*57:03 CTL can mediate inhibition of viral replication when IW9 epitope is presented in the 
context of B*57:03 or B*58:01 alleles. 
 
             
Figure 30: Comparison of the Inhibitory Activity of B*57:03 CTL Targeting IW9 Epitope 
Presented by HLA-B*57:03 or B*58:01 Alleles. No difference was observed in the inhibitory 
capacity of B*57:03 CTL targeting IW9 epitope presented by HLA-B*57:03 or B*58:01 alleles 















CHAPTER FIVE: Discussion 
 
Although several studies have provided evidences on the critical role of HIV-specific CTL in 
the immune containment of HIV infection (Walker and McMichael, 2012), developing a cross-
reactive HIV CTL based vaccine remains an elusive goal. HIV-specific CTL exert potent 
antiviral effects that are mediated by two distinct mechanisms. The first requires direct contact 
of the CTL with infected target cells, resulting in cytolysis; the second is mediated by soluble 
inhibitory factors produced by CTL. Both processes require antigen-specific class I HLA 
restricted activation through the T-cell receptor (TCR) (Yang et al., 1997).  
Class I HLA alleles have been shown to play a major role in immune mediated control 
of HIV infection (Goulder and Walker, 2012), but the extent of contributions of responses 
restricted by different class I alleles within a given individual has not been fully evaluated. 
Studies have also demonstrated that multiple class I HLA alleles can restrict identical epitopes 
(supertopes) due to the homology of the amino acids within the major peptide binding pockets 
of the peptide binding cleft (Sette and Sidney, 1999). However, it is not clear if supertopes 
presented in the context of closely related HLA alleles would induce functional equivalent 
CTL.  
In this study, we investigated the inhibitory activity of CTL targeting identical epitopes 
presented by class I HLA alleles from the same supertype. We developed a new GXR-VIA that 
can assess the influence of class I HLA molecules on CTL inhibitory activity and evaluated the 
performance of the assay against the well-established ELISA-VIA. The GXR-VIA was used to 
evaluate the inhibitory capacity of CTL targeting identical epitopes restricted by closely related 
class I HLA alleles. We focussed on the two most common supertypes in Zulu/Xhosa ethnicity 
in KwaZulu-Natal, South Africa, namely; the B7 supertype (HLA-B*81:01 and B*42:01 
alleles restricting TL9 epitope) and B57 supertype (HLA-B*57:03 and B*58:01 alleles 
restricting IW9 epitope). Furthermore, we assessed the functional consequence of mutant 
(Q182S)-TL9 epitope commonly selected by HIV infected individuals expressing B*42:01 
allele (Leslie et al., 2006b) and B*81:01 allele (Ntale et al., 2012), on TL9-specific CTL. 
GXR-VIA and ELISA-VIA were concurrently performed on 8 HIV infected subjects’ 
CTL to assess their inhibitory activity. Our data showed no difference in the inhibitory activity 
of all the CTLs tested using GXR-VIA or ELISA-VIA. In addition, significant correlation was 
observed between GXR-VIA and ELISA-VIA. These data suggest that the GXR-VIA can 




The unique benefit of GXR-VIA is its ability to evaluate the role of class I HLA 
restriction on CTL inhibitory activity. One notable advantage of the GXR-VIA over the 
ELISA-VIA is the relatively shorter assay duration of 3 days instead of 7 days for the ELISA-
VIA, thus minimizing variations introduced by long-term culture, especially since multiple 
dilutions need to be tested. GXR-VIA is also significantly cheaper than ELISA-VIA.       
The accurate assessment of the antiviral activity of HIV-specific CTL is a crucial step 
towards identifying the immune correlates of vaccine efficacy. It is possible that there is a 
hierarchy of efficacious HIV-specific CTL responses in individuals restricting identical 
epitopes (D'Souza and Altfeld, 2008).  
Our data demonstrate no significant difference in the inhibitory activity of CTL 
targeting identical TL9 epitopes presented in the context of HLA-B*81:01 or HLA-B*42:01 
alleles. The reasons behind this functional equivalence is not clear. Previous studies have 
identified TL9 epitope presented by closely related B*81:01 or B*42:01 alleles to be 
promiscuous (Leslie et al., 2006b), and the TCRs recognising promiscuous epitopes are highly 
cross reactive (Birnbaum et al., 2014), we can therefore speculate that there could be similarity 
in the biophysical properties of the TCRs of subjects with closely related HLA alleles. The 
ability of one TCR to bind multiple orientations of identical epitopes restricted by closely 
related alleles have also been proposed (Morris and Allen, 2012, Kloverpris et al., 2015). This 
could also be a contributing factor to the ability of CTL from B*81:01 or B*42:01 subjects to 
recognise TL9 epitope with comparable affinity.  
Minor differences between closely related class I HLA alleles (micrpolymorphism), 
even of a single amino acid, can have profound impact on both T-cell immunity and disease 
outcome during a range of infections, including HIV (Gao et al., 2001b, Jin et al., 2002, 
Geldmacher et al., 2009, Goulder and Walker, 2012, Kloverpris et al., 2012a). This observation 
has been partly explained by selection of escape mutations that have different consequences on 
viral fitness (Matthews et al., 2008, Carlson et al., 2012, Kloverpris et al., 2012b). Interestingly, 
our data demonstrate that CTL from B*81:01 and B*42:01 background are able to inhibit HIV 
replication when promiscuous TL9 epitope is presented by closely related HLA-B*81:01 or 
B*42:01 alleles despite the potential differences between the closely related class I HLA 
molecule presenting promiscuous TL9 epitope. Overall, our data support the notion that 
promiscuous epitopes commonly restricted by closely related class I HLA alleles can be used 
to design supertype CTL based vaccine.  
The CTL pressure has been associated with the appearance of escape mutations in HIV. 




stability of peptides on class I HLA allele, or TCR recognition of the Peptide/HLA complex 
(Yokomaku et al., 2004). Of note, these categories are not mutually exclusive; for example, 
anchor residue mutations may alter the peptide secondary structure, affecting both HLA 
binding and TCR recognition (Reid et al., 1996). Mutation in residue Q182, located at the 
proximal to the promiscuous TL9 epitope binding, has been frequently identified as immune 
escape in the B*81:01 and B*42:01 positive individuals (Leslie et al., 2006b, Ntale et al., 2012). 
The implication of this mutation on the antiviral efficacy of CTL when TL9 epitope harbouring 
it is presented has not been fully evaluated. 
We sought to determine the functional consequence of CTL when in-vivo occurring 
mutant (Q182S)-TL9 epitope is presented in the context of B*81:01 allele as opposed to 
B*42:01 allele. We first generated recombinant virus harbouring Q182S mutation within p24 
Gag TL9 epitope and tested its infectivity relative to the wildtype NL4-3. In agreement with 
other studies (Friedrich et al., 2004, Peyerl et al., 2004, Matano et al., 2004, Fernandez et al., 
2005, Martinez-Picado et al., 2006, Wright et al., 2010), we found that escape mutation at 
position Q182 within TL9 epitope has a minimal effect on the viral infectivity.    
Next, we tested the functional consequence of mutant (Q182S)-TL9 epitope presented 
in the context of HLA-B*81:01 or B*42:01 alleles to TL9-specific CTL. Our data showed that 
the mutant (Q182)-TL9 epitope can be recognised by TL9-specific CTLs from B*81:01 and 
B*42:01 subjects when it is presented by either HLA-B*81:01 or B*42:01 alleles. 
Interestingly, the inhibitory activity observed when mutant (Q182)-TL9 epitope is presented in 
the context of HLA-B*81:01 allele is not different from the inhibitory activity observed when 
mutant (Q182)-TL9 epitope is presented in the context of HLA-B*42:01 allele. These data 
agree with the study that demonstrated the effectiveness of CTL to supress replication of HIV 
escape mutants (Pohlmeyer et al., 2013). Other studies have also proposed the flexibility of the 
CTL’s TCR to recognizing mutant epitopes (Buseyne and Riviere, 2001, McKinney et al., 
2004, Yu et al., 2005, Geldmacher et al., 2007). In contrast, some studies reported that 
substitutions in immunodominant epitopes might abrogate the ability of CTL to recognize 
mutant epitopes (Goulder et al., 1997, Iversen et al., 2006). Furthermore, variations of epitopes 
restricted by class I HLA allele are not efficiently cross recognized (Turnbull et al., 2006). 
Thus, our data suggest that TCR of TL9-specific CTLs from B*81:01 and B*42:01 subjects 
can cross recognize mutant (Q182)-TL9 epitope presented in the context of HLA-B*81:01 or 
B*42:01 alleles, thereby mediating inhibition of viral replication.     
Growing numbers of studies suggest that CTL targeting Gag, particularly the HIV-p24 




al., 2006, Borghans et al., 2007, Kiepiela et al., 2007, Pereyra et al., 2008, Rolland et al., 2008). 
The closely related class I HLA-B*57:03 and B*58:01 alleles are notable for restricting 
immunodominant CTL responses that effectively supress HIV viremia and for being associated 
with improved long-term clinical outcomes of HIV infection (Kaslow et al., 1996, Migueles et 
al., 2000, O'Brien et al., 2001, Altfeld et al., 2003). Three of the epitopes that are most strongly 
targeted by HLA-B*57:03 and B*58:01 alleles are ISPRTLNAW (IW9; Gag 147 to 155) 
(Draenert et al., 2004a), KAFSPEVIPMF (KF11; Gag 162 to 172) (Crawford et al., 2007), and 
TSTLQEQIAW (TW10; Gag 240 to 249) (Leslie et al., 2004). IW9 is the well characterized 
p24 epitope frequently restricted early by HLA-B*57:03 and B*58:01 alleles (Matthews et al., 
2008). Early CTL responses are thought to be more important for control of HIV infection than 
later CTL responses, both because they limit peak viremia and impose early fitness costs on 
the virus (Cao et al., 2003b, Streeck and Nixon, 2010).  
We assessed the inhibitory capacity CTL targeting IW9 epitope presented in the context 
of HLA-B*57:03 or B*58:01 alleles. Surprisingly, we observed no statistical difference in the 
inhibitory capacity of IW9-spepcific CTLs from B*57:03 subjects when IW9 epitope is 
presented by B*57:03 or B*58:01 alleles.       
Examinations of TL9 and IW9 supertopes presented by alleles within B7 and B57 
supertypes respectively, as described above, suggest that these findings in which equivalence 
inhibitory activity of CTL targeting identical epitopes is observed, may be a general 
phenomenon for closely related class I HLA alleles.     
             Our study has notable limitations. Although the GXR cell lines we used as target cells 
have been genetically engineered to overexpress class I HLA of interest, the levels of 
expression of the specific class I HLA molecule in one target cell line as opposed the other 
target cell line is unknown and this could have introduced bias to the inhibition we observed in 
the context of one target cell line compared to the other target cell line. Samples size used in 
this study is low and this might have affected our data analysis. Another limitation is that we 
used expanded TL9-specific CTLs, this might have resulted in some non-specific inhibition 
that would have been considered as inhibition mediated by epitope presentation. 
In conclusion, we have demonstrated that the inhibitory activity of CTL targeting 
identical TL9 epitopes presented by closely related B*81:01 or B*42:01 alleles is functionally 
equivalent. We have also demonstrated that TL9-specific CTL can mediate inhibition of viral 
replication when mutant (Q182S)-TL9 epitope is presented by B*81:01 or B*42:01 alleles. 
Furthermore, we have shown that IW9-specific CTL obtained from B*57:03 subjects can 




alleles. Thus, promiscuous TL9 and IW9 epitopes could be immunogenic. These findings are 
relevant for HIV vaccine approach that seeks to identify immunogenic epitopes that can be 
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Bovine Saline Albumin (BSA) 
 
0.5g of BSA was added to 100 ml of distilled water. 
 
Phosphate Buffer Saline (PBS) 
 
One PBS table was dissolved per 100 ml distilled water. The solution was adjusted to a pH of 




1 ml of BSA solution was added to 49 ml of PBS. 
 
2% Paraformaldehyde (PFA) 
 





To 500 ml RPMI (Sigma) add: 
50 ml heat inactivated and filter sterilized fetal calf serum 
5 ml L-glutamin 
5 ml Penstrep Fungizone (100X) 
5 ml Hepes 




28 000 of interleukin-2 was added to 500 ml R10 medium to produce R10 medium containing 
56 unit/ml of interleukin-2. The medium was stored at 4 ºC with an expiry time of 14 days. 
